Please select a condition.
| Pathway | hits | oddsratio | pvalue |
| Pantothenate and coa biosynthesis | C00010,C01134,C00882,C00097 | 23.1594202899 | 0.00016247442585 |
| Galactose metabolism | C00159,C01835,C00029,C00052 | 6.61697722567 | 0.0065590822245 |
| Nucleotide sugars metabolism | C00029,C00052 | 9.92546583851 | 0.0274962945456 |
| Hartnup disorder | C00047,C00183 | 9.92546583851 | 0.0274962945456 |
| Glutaric aciduria type i | C00489 | inf | 0.0291616038882 |
| Gamma-glutamyltransferase deficiency | C00051 | inf | 0.0291616038882 |
| Glutathione metabolism | C00051,C00097 | 8.6847826087 | 0.0336663073396 |
| Lactose synthesis | C00029,C00052 | 7.71980676329 | 0.0403078977421 |
| Transcription/translation | C00047,C00183,C00097 | 4.16869565217 | 0.0500947105166 |
| Beta-alanine metabolism | C00010,C00106 | 6.3162055336 | 0.0548669078543 |
| Hypermethioninemia | C00097 | 34.7391304348 | 0.0574384503769 |
| Lysinuric protein intolerance | C00047 | 34.7391304348 | 0.0574384503769 |
| Saccharopinuria/hyperlysinemia ii | C00047 | 34.7391304348 | 0.0574384503769 |
| Ump synthase deiciency (orotic aciduria) | C00106 | 34.7391304348 | 0.0574384503769 |
| Glutaric aciduria type iii | C00489,C00047 | 5.78985507246 | 0.062719292017 |
| Glutathione synthetase deficiency | C00051 | 17.3695652174 | 0.0848584227297 |
| Insulin signalling | C00010,C00029 | 4.08695652174 | 0.106554179532 |
| Biotin metabolism | C00047 | 11.5797101449 | 0.111448492771 |
| Biotinidase deficiency | C00047 | 11.5797101449 | 0.111448492771 |
| Phenylacetate metabolism | C00010 | 8.6847826087 | 0.137234751748 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | C00106 | 8.6847826087 | 0.137234751748 |
| Citric acid cycle | C00010,C00016 | 3.30848861284 | 0.145632641109 |
| Citrullinemia type i | C00047 | 6.94782608696 | 0.162242440103 |
| Taurine and hypotaurine metabolism | C00097 | 5.78985507246 | 0.186495976216 |
| Pyruvaldehyde degradation | C00051 | 5.78985507246 | 0.186495976216 |
| Cysteine metabolism | C00097 | 4.96273291925 | 0.210018984133 |
| Glycerol phosphate shuttle | C00016 | 4.96273291925 | 0.210018984133 |
| Riboflavin metabolism | C00016 | 4.34239130435 | 0.232834320331 |
| Butyrate metabolism | C00010 | 4.34239130435 | 0.232834320331 |
| Ketone body metabolism | C00010 | 3.85990338164 | 0.254964099552 |
| Pyrimidine metabolism | C00106,C00299 | 2.04347826087 | 0.282593434058 |
| 2-oxobutanoate degradation | C00010 | 2.89492753623 | 0.317450634257 |
| Lysine degradation | C00047 | 2.89492753623 | 0.317450634257 |
| Oxidation of branched chain fatty acids | C00010 | 2.67224080268 | 0.33704535289 |
| Beta oxidation of very long chain fatty acids | C00010 | 2.67224080268 | 0.33704535289 |
| Starch and sucrose metabolism | C00029 | 2.67224080268 | 0.33704535289 |
| Ethanol degradation | C00010 | 2.48136645963 | 0.356054805137 |
| Transfer of acetyl groups into mitochondria | C00010 | 2.31594202899 | 0.37449714962 |
| Carnitine synthesis | C00047 | 2.17119565217 | 0.392389960596 |
| Glutamate metabolism | C00051 | 2.04347826087 | 0.409750247437 |
| Fructose and mannose degradation | C00159 | 2.04347826087 | 0.409750247437 |
| Propanoate metabolism | C00183 | 2.04347826087 | 0.409750247437 |
| Methionine metabolism | C00097 | 1.51039697543 | 0.503614916727 |
| Glycine, serine and threonine metabolism | C00097 | 1.38956521739 | 0.531330699651 |
| Fatty acid metabolism | C00010 | 1.24068322981 | 0.569919416887 |
| Fatty acid biosynthesis | C06424 | 1.1206171108 | 0.60520985868 |
| Valine, leucine and isoleucine degradation | C00183 | 0.992546583851 | 0.647634230862 |
| Bile acid biosynthesis | C00010 | 0.723731884058 | 0.755584241952 |
| Pathway | hits | oddsratio | pvalue |
| Transcription/translation | C00148,C00073,C00407,C00047,C00188,C00183,C00097 | 8.59139784946 | 0.000113814598854 |
| Pantothenate and coa biosynthesis | C00010,C01134,C00882,C00097 | 17.1827956989 | 0.000445665830761 |
| Hypermethioninemia | C00073,C00097 | inf | 0.00152735351291 |
| Galactose metabolism | C01835,C00159,C00029,C00052,C00668 | 6.4435483871 | 0.0028700617109 |
| Nucleotide sugars metabolism | C00029,C00052,C00668 | 12.8870967742 | 0.00432890704034 |
| Hartnup disorder | C00047,C00407,C00183 | 12.8870967742 | 0.00432890704034 |
| Glycine n-methyltransferase deficiency | C00073 | inf | 0.0385078219013 |
| Glutaric aciduria type i | C00489 | inf | 0.0385078219013 |
| Gamma-glutamyltransferase deficiency | C00051 | inf | 0.0385078219013 |
| Methionine adenosyltransferase deficiency | C00073 | inf | 0.0385078219013 |
| Glutathione metabolism | C00051,C00097 | 6.4435483871 | 0.0553086850208 |
| Lactose synthesis | C00029,C00052 | 5.72759856631 | 0.065824640661 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | C00073 | 25.7741935484 | 0.0754882902897 |
| Lysinuric protein intolerance | C00047 | 25.7741935484 | 0.0754882902897 |
| Iminoglycinuria | C00148 | 25.7741935484 | 0.0754882902897 |
| Saccharopinuria/hyperlysinemia ii | C00047 | 25.7741935484 | 0.0754882902897 |
| Prolinemia type ii | C00148 | 25.7741935484 | 0.0754882902897 |
| Ump synthase deiciency (orotic aciduria) | C00106 | 25.7741935484 | 0.0754882902897 |
| Beta-alanine metabolism | C00010,C00106 | 4.6862170088 | 0.088546273056 |
| Oxidation of branched chain fatty acids | C00010,C02571 | 4.29569892473 | 0.100628719708 |
| Beta oxidation of very long chain fatty acids | C00010,C02571 | 4.29569892473 | 0.100628719708 |
| Starch and sucrose metabolism | C00029,C00668 | 4.29569892473 | 0.100628719708 |
| Glutaric aciduria type iii | C00489,C00047 | 4.29569892473 | 0.100628719708 |
| Hyperprolinemia type i | C00148 | 12.8870967742 | 0.111003746125 |
| Glutathione synthetase deficiency | C00051 | 12.8870967742 | 0.111003746125 |
| Cystathionine beta-synthase deficiency | C00073 | 12.8870967742 | 0.111003746125 |
| Hyperprolinemia type ii | C00148 | 8.59139784946 | 0.14511391414 |
| Biotin metabolism | C00047 | 8.59139784946 | 0.14511391414 |
| Biotinidase deficiency | C00047 | 8.59139784946 | 0.14511391414 |
| Insulin signalling | C00010,C00029 | 3.03225806452 | 0.166149762653 |
| Phenylacetate metabolism | C00010 | 6.4435483871 | 0.177876015633 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | C00106 | 6.4435483871 | 0.177876015633 |
| Citrullinemia type i | C00047 | 5.15483870968 | 0.209344876279 |
| Citric acid cycle | C00010,C00016 | 2.45468509985 | 0.222146504722 |
| Methionine metabolism | C00073,C00097 | 2.3431085044 | 0.236354836133 |
| Taurine and hypotaurine metabolism | C00097 | 4.29569892473 | 0.239573029157 |
| Pyruvaldehyde degradation | C00051 | 4.29569892473 | 0.239573029157 |
| Glycine, serine and threonine metabolism | C00188,C00097 | 2.14784946237 | 0.264832013276 |
| Cysteine metabolism | C00097 | 3.68202764977 | 0.268610813247 |
| Glycerol phosphate shuttle | C00016 | 3.68202764977 | 0.268610813247 |
| Riboflavin metabolism | C00016 | 3.22177419355 | 0.296506467569 |
| Spermidine and spermine biosynthesis | C00073 | 3.22177419355 | 0.296506467569 |
| Butyrate metabolism | C00010 | 3.22177419355 | 0.296506467569 |
| Betaine metabolism | C00073 | 2.86379928315 | 0.323306221186 |
| Ketone body metabolism | C00010 | 2.86379928315 | 0.323306221186 |
| 2-oxobutanoate degradation | C00010 | 2.14784946237 | 0.397563999551 |
| Lysine degradation | C00047 | 2.14784946237 | 0.397563999551 |
| Pyrimidine metabolism | C00106,C00299 | 1.51612903226 | 0.403410167651 |
| Valine, leucine and isoleucine degradation | C00407,C00183 | 1.51612903226 | 0.403410167651 |
| Ethanol degradation | C00010 | 1.84101382488 | 0.442354328062 |
| Transfer of acetyl groups into mitochondria | C00010 | 1.71827956989 | 0.463447308561 |
| Carnitine synthesis | C00047 | 1.61088709677 | 0.483718484625 |
| Pentose phosphate pathway | C00668 | 1.51612903226 | 0.50320080596 |
| Glutamate metabolism | C00051 | 1.51612903226 | 0.50320080596 |
| Fructose and mannose degradation | C00159 | 1.51612903226 | 0.50320080596 |
| Propanoate metabolism | C00183 | 1.51612903226 | 0.50320080596 |
| Inositol metabolism | C00668 | 1.43189964158 | 0.521925863921 |
| Inositol phosphate metabolism | C00668 | 1.35653650255 | 0.539923949044 |
| Hypoacetylaspartia | C02571 | 1.35653650255 | 0.539923949044 |
| Glycolysis | C00668 | 1.28870967742 | 0.557224106072 |
| Prolidase deficiency(pd) | C00148 | 1.07392473118 | 0.619985630051 |
| Arginine and proline metabolism | C00148 | 1.03096774194 | 0.634191774722 |
| Gluconeogenesis | C00668 | 0.991315136476 | 0.647850891652 |
| Fatty acid metabolism | C00010 | 0.920506912442 | 0.673613867414 |
| Fatty acid biosynthesis | C06424 | 0.831425598335 | 0.708669610511 |
| Bile acid biosynthesis | C00010 | 0.536962365591 | 0.845822354304 |
| Pathway | hits | oddsratio | pvalue |
| Transcription/translation | C00148,C00123,C00073,C00407,C00064,C00041,C00079,C00047,C00188,C00183,C00097 | 9.57407407407 | 1.20985112599e-06 |
| Hartnup disorder | C00047,C00041,C00123,C00407,C00183 | 18.4953703704 | 0.000129710636765 |
| Citrullinemia type i | C00041,C00047,C00064,C00327 | 29.5925925926 | 0.00025468574764 |
| Pantothenate and coa biosynthesis | C00010,C01134,C00882,C00097 | 9.86419753086 | 0.00285129833583 |
| Hypermethioninemia | C00073,C00097 | inf | 0.00421819576263 |
| Ornithine transcarbamylase deficiency (otc deficiency) | C00041,C00327,C00064 | 11.0972222222 | 0.00799335338733 |
| Glutaric aciduria type iii | C00489,C00408,C00047,C00956 | 5.91851851852 | 0.0109034699484 |
| Nucleotide sugars metabolism | C00029,C00052,C00668 | 7.39814814815 | 0.0173235896325 |
| Galactose metabolism | C01835,C00159,C00029,C00052,C00668 | 3.69907407407 | 0.0216325875561 |
| Phenylacetate metabolism | C00010,C00064 | 9.86419753086 | 0.0368441835589 |
| Lysine degradation | C00408,C00047,C00956 | 4.43888888889 | 0.0482392871813 |
| Glycine n-methyltransferase deficiency | C00073 | inf | 0.0644028103045 |
| Lactic acidemia | C00041 | inf | 0.0644028103045 |
| Glutaric aciduria type i | C00489 | inf | 0.0644028103045 |
| Pyruvate dehydrogenase complex deficiency | C00186 | inf | 0.0644028103045 |
| Gamma-glutamyltransferase deficiency | C00051 | inf | 0.0644028103045 |
| Methionine adenosyltransferase deficiency | C00073 | inf | 0.0644028103045 |
| Pyruvaldehyde degradation | C03451,C00051 | 5.91851851852 | 0.0708095637404 |
| Glycine, serine and threonine metabolism | C00065,C00597,C00188,C00097 | 2.69023569024 | 0.0857652596156 |
| Glycerol phosphate shuttle | C00093,C00016 | 4.93209876543 | 0.0903621123752 |
| Tyrosinemia type 3 (tyro3) | C00079 | 14.7962962963 | 0.124587424846 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | C00079 | 14.7962962963 | 0.124587424846 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | C00073 | 14.7962962963 | 0.124587424846 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | C00186 | 14.7962962963 | 0.124587424846 |
| Molybdenium cofactor deficiency | C00385 | 14.7962962963 | 0.124587424846 |
| Lysinuric protein intolerance | C00047 | 14.7962962963 | 0.124587424846 |
| Iminoglycinuria | C00148 | 14.7962962963 | 0.124587424846 |
| Saccharopinuria/hyperlysinemia ii | C00047 | 14.7962962963 | 0.124587424846 |
| Prolinemia type ii | C00148 | 14.7962962963 | 0.124587424846 |
| Xanthine dehydrogenase deficiency (xanthinuria) | C00385 | 14.7962962963 | 0.124587424846 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | C00186 | 14.7962962963 | 0.124587424846 |
| Ump synthase deiciency (orotic aciduria) | C00106 | 14.7962962963 | 0.124587424846 |
| Glutathione metabolism | C00051,C00097 | 3.69907407407 | 0.133156327116 |
| Urea cycle | C00041,C00327,C00064 | 2.61111111111 | 0.136554606584 |
| Lactose synthesis | C00029,C00052 | 3.28806584362 | 0.155911387257 |
| Pyruvate carboxylase deficiency | C00041 | 7.39814814815 | 0.180834728157 |
| Hyperprolinemia type i | C00148 | 7.39814814815 | 0.180834728157 |
| Glutathione synthetase deficiency | C00051 | 7.39814814815 | 0.180834728157 |
| Cystathionine beta-synthase deficiency | C00073 | 7.39814814815 | 0.180834728157 |
| Methionine metabolism | C00073,C00065,C00097 | 2.11375661376 | 0.200499425568 |
| Beta-alanine metabolism | C00010,C00106 | 2.69023569024 | 0.203120404602 |
| Oxidation of branched chain fatty acids | C00010,C02571 | 2.46604938272 | 0.22723684157 |
| Beta oxidation of very long chain fatty acids | C00010,C02571 | 2.46604938272 | 0.22723684157 |
| Starch and sucrose metabolism | C00029,C00668 | 2.46604938272 | 0.22723684157 |
| Hyperprolinemia type ii | C00148 | 4.93209876543 | 0.233406595078 |
| Argininosuccinic aciduria | C00327 | 4.93209876543 | 0.233406595078 |
| Biotin metabolism | C00047 | 4.93209876543 | 0.233406595078 |
| Biotinidase deficiency | C00047 | 4.93209876543 | 0.233406595078 |
| Gluconeogenesis | C00186,C00597,C00668 | 1.84953703704 | 0.251961055963 |
| Phenylketonuria | C00079 | 3.69907407407 | 0.282547197957 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | C00106 | 3.69907407407 | 0.282547197957 |
| Glutamate metabolism | C00064,C00051 | 1.84953703704 | 0.32405812062 |
| Ammonia recycling | C00065,C00064 | 1.84953703704 | 0.32405812062 |
| Insulin signalling | C00010,C00029 | 1.74074074074 | 0.347853812982 |
| Glycerolipid metabolism | C00093,C00597 | 1.74074074074 | 0.347853812982 |
| Hypoacetylaspartia | C02571,C00041 | 1.64403292181 | 0.371331502581 |
| Pyruvate metabolism | C00186,C03451 | 1.64403292181 | 0.371331502581 |
| Leigh syndrome | C00186,C03451 | 1.64403292181 | 0.371331502581 |
| Homocysteine degradation | C00065 | 2.46604938272 | 0.371429999001 |
| Taurine and hypotaurine metabolism | C00097 | 2.46604938272 | 0.371429999001 |
| Alanine metabolism | C00041 | 2.46604938272 | 0.371429999001 |
| Glycolysis | C00597,C00668 | 1.55750487329 | 0.39443311935 |
| Pyrimidine metabolism | C00106,C00064,C00299 | 1.34511784512 | 0.410169486712 |
| Valine, leucine and isoleucine degradation | C00123,C00407,C00183 | 1.34511784512 | 0.410169486712 |
| Cysteine metabolism | C00097 | 2.11375661376 | 0.411582554234 |
| Citric acid cycle | C00010,C00016 | 1.40917107584 | 0.439320256945 |
| Riboflavin metabolism | C00016 | 1.84953703704 | 0.449126590797 |
| Spermidine and spermine biosynthesis | C00073 | 1.84953703704 | 0.449126590797 |
| Butyrate metabolism | C00010 | 1.84953703704 | 0.449126590797 |
| Prolidase deficiency(pd) | C00148,C00327 | 1.28663446055 | 0.48221541721 |
| Betaine metabolism | C00073 | 1.64403292181 | 0.484234397873 |
| Vitamin b6 metabolism | C00847 | 1.64403292181 | 0.484234397873 |
| Ketone body metabolism | C00010 | 1.64403292181 | 0.484234397873 |
| Arginine and proline metabolism | C00148,C00327 | 1.23302469136 | 0.502851310671 |
| Aspartate metabolism | C00327 | 1.34511784512 | 0.54777344062 |
| Glucose-alanine cycle | C00041 | 1.34511784512 | 0.54777344062 |
| Purine metabolism | C00385,C00294,C00064 | 1.05687830688 | 0.555417142104 |
| Phenylalanine and tyrosine metabolism | C00079 | 1.23302469136 | 0.576494526956 |
| 2-oxobutanoate degradation | C00010 | 1.23302469136 | 0.576494526956 |
| Ethanol degradation | C00010 | 1.05687830688 | 0.62849318979 |
| Selenoamino acid metabolism | C00041 | 1.05687830688 | 0.62849318979 |
| Sphingolipid metabolism | C00065 | 1.05687830688 | 0.62849318979 |
| Amino sugar metabolism | C00329 | 1.05687830688 | 0.62849318979 |
| Mitochondrial electron transport chain | C00093 | 1.05687830688 | 0.62849318979 |
| Transfer of acetyl groups into mitochondria | C00010 | 0.986419753086 | 0.652006279045 |
| Carnitine synthesis | C00047 | 0.924768518519 | 0.674005882093 |
| Pentose phosphate pathway | C00668 | 0.87037037037 | 0.694591044534 |
| Fructose and mannose degradation | C00159 | 0.87037037037 | 0.694591044534 |
| Propanoate metabolism | C00183 | 0.87037037037 | 0.694591044534 |
| Phospholipid biosynthesis | C00093 | 0.822016460905 | 0.713854224064 |
| Inositol metabolism | C00668 | 0.822016460905 | 0.713854224064 |
| Inositol phosphate metabolism | C00668 | 0.778752436647 | 0.73188173572 |
| Fatty acid metabolism | C00010 | 0.528439153439 | 0.850213753294 |
| Fatty acid biosynthesis | C06424 | 0.477299880526 | 0.876468231491 |
| Tryptophan metabolism | C01717 | 0.448372615039 | 0.891320991583 |
| Bile acid biosynthesis | C00010 | 0.30825617284 | 0.958026115536 |
| Pathway | hits | oddsratio | pvalue |
| Spermidine and spermine biosynthesis | C00073,C00170,C00315 | 13.775862069 | 0.00365245956438 |
| Glycine n-methyltransferase deficiency | C00073 | inf | 0.0361881785284 |
| Pyruvate dehydrogenase complex deficiency | C00186 | inf | 0.0361881785284 |
| Methionine adenosyltransferase deficiency | C00073 | inf | 0.0361881785284 |
| Pyrimidine metabolism | C00055,C00295,C02642,C00299 | 3.44396551724 | 0.0437562109577 |
| Methionine metabolism | C00073,C00170,C00315 | 3.93596059113 | 0.0569621745881 |
| Prolidase deficiency(pd) | C00086,C00122,C00300 | 3.75705329154 | 0.0629259129355 |
| Arginine and proline metabolism | C00086,C00122,C00300 | 3.59370314843 | 0.0691577492851 |
| Hypermethioninemia | C00073 | 27.5517241379 | 0.0710247503888 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | C00300 | 27.5517241379 | 0.0710247503888 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | C00073 | 27.5517241379 | 0.0710247503888 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | C00186 | 27.5517241379 | 0.0710247503888 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | C00300 | 27.5517241379 | 0.0710247503888 |
| Dihydropyrimidinase deficiency | C02642 | 27.5517241379 | 0.0710247503888 |
| Beta ureidopropionase deficiency | C02642 | 27.5517241379 | 0.0710247503888 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | C00186 | 27.5517241379 | 0.0710247503888 |
| Ump synthase deiciency (orotic aciduria) | C00295 | 27.5517241379 | 0.0710247503888 |
| Gluconeogenesis | C00186,C00003,C00668 | 3.44396551724 | 0.0756483343955 |
| Transcription/translation | C00055,C00123,C00073 | 3.30620689655 | 0.0823879274674 |
| Oxidation of branched chain fatty acids | C03017,C00318 | 4.59195402299 | 0.0906803499602 |
| Mitochondrial electron transport chain | C00122,C00003 | 4.23872679045 | 0.102079941173 |
| Cystathionine beta-synthase deficiency | C00073 | 13.775862069 | 0.10456176301 |
| Carnitine synthesis | C00318,C00003 | 3.67356321839 | 0.125890186364 |
| Urea cycle | C00086,C00122 | 3.06130268199 | 0.163537362345 |
| Pyruvate metabolism | C00227,C00186 | 3.06130268199 | 0.163537362345 |
| Leigh syndrome | C00227,C00186 | 3.06130268199 | 0.163537362345 |
| Glycolysis | C00003,C00668 | 2.9001814882 | 0.176460726147 |
| Citric acid cycle | C00122,C00003 | 2.62397372742 | 0.202685499884 |
| Ornithine transcarbamylase deficiency (otc deficiency) | C00295 | 4.59195402299 | 0.226684661209 |
| Glycerol phosphate shuttle | C00003 | 3.93596059113 | 0.254435211645 |
| Malate-aspartate shuttle | C00003 | 3.93596059113 | 0.254435211645 |
| Nucleotide sugars metabolism | C00668 | 3.44396551724 | 0.281157963915 |
| Hartnup disorder | C00123 | 3.44396551724 | 0.281157963915 |
| Pantothenate and coa biosynthesis | C01134 | 3.06130268199 | 0.306892165685 |
| Betaine metabolism | C00073 | 3.06130268199 | 0.306892165685 |
| Ketone body metabolism | C00003 | 3.06130268199 | 0.306892165685 |
| Phosphatidylinositol phosphate metabolism | C00055 | 2.75517241379 | 0.331675520904 |
| Aspartate metabolism | C00122 | 2.50470219436 | 0.355544252301 |
| Glucose-alanine cycle | C00003 | 2.50470219436 | 0.355544252301 |
| Nicotinate and nicotinamide metabolism | C00003 | 2.29597701149 | 0.378533161256 |
| Beta-alanine metabolism | C02642 | 2.29597701149 | 0.378533161256 |
| Phenylalanine and tyrosine metabolism | C00122 | 2.29597701149 | 0.378533161256 |
| 2-oxobutanoate degradation | C00003 | 2.29597701149 | 0.378533161256 |
| Beta oxidation of very long chain fatty acids | C00318 | 2.11936339523 | 0.400675685201 |
| Starch and sucrose metabolism | C00668 | 2.11936339523 | 0.400675685201 |
| Ethanol degradation | C00003 | 1.96798029557 | 0.422003952631 |
| Sphingolipid metabolism | C00319 | 1.96798029557 | 0.422003952631 |
| Transfer of acetyl groups into mitochondria | C00003 | 1.8367816092 | 0.442548835833 |
| Pentose phosphate pathway | C00668 | 1.62068965517 | 0.48140595882 |
| Glutamate metabolism | C00003 | 1.62068965517 | 0.48140595882 |
| Ammonia recycling | C00003 | 1.62068965517 | 0.48140595882 |
| Phospholipid biosynthesis | C00307 | 1.530651341 | 0.499774106678 |
| Inositol metabolism | C00668 | 1.530651341 | 0.499774106678 |
| Glycerolipid metabolism | C00003 | 1.530651341 | 0.499774106678 |
| Inositol phosphate metabolism | C00668 | 1.4500907441 | 0.517470777432 |
| Hypoacetylaspartia | C00122 | 1.4500907441 | 0.517470777432 |
| Histidine metabolism | C00003 | 1.19790104948 | 0.58203436289 |
| Galactose metabolism | C00668 | 1.14798850575 | 0.596734209447 |
| Glycine, serine and threonine metabolism | C00300 | 1.10206896552 | 0.610900455017 |
| Valine, leucine and isoleucine degradation | C00123 | 0.787192118227 | 0.727250457706 |
| Tyrosine metabolism | C00122 | 0.744641192917 | 0.745830880811 |
| Purine metabolism | C00147 | 0.626175548589 | 0.801188073362 |
| Pathway | hits | oddsratio | pvalue |
| Hartnup disorder | C00135,C00062,C00047,C00183 | 18.2628571429 | 0.000418670906606 |
| Lysinuric protein intolerance | C00062,C00047 | inf | 0.00190814543162 |
| Spermidine and spermine biosynthesis | C00170,C00077,C00315 | 11.4142857143 | 0.00589063468426 |
| Transcription/translation | C00135,C00062,C00047,C00183,C00064 | 4.96273291925 | 0.00744498993051 |
| Citrullinemia type i | C00047,C00064 | 11.4142857143 | 0.0253338322036 |
| Ornithine transcarbamylase deficiency (otc deficiency) | C00077,C00064 | 9.13142857143 | 0.0344144458674 |
| Pyruvate dehydrogenase complex deficiency | C00186 | inf | 0.0431137724551 |
| Histidinemia | C00135 | inf | 0.0431137724551 |
| Sarcosinemia | C00213 | inf | 0.0431137724551 |
| Ornithine aminotransferase deficiency (oat deficiency) | C00077 | inf | 0.0431137724551 |
| Urea cycle | C00062,C00064,C00077 | 4.02857142857 | 0.0548886492502 |
| Pyruvate metabolism | C00227,C00186,C00074 | 4.02857142857 | 0.0548886492502 |
| Leigh syndrome | C00227,C00186,C00074 | 4.02857142857 | 0.0548886492502 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | C00186 | 22.8285714286 | 0.0843193994786 |
| Saccharopinuria/hyperlysinemia ii | C00047 | 22.8285714286 | 0.0843193994786 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | C00213 | 22.8285714286 | 0.0843193994786 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | C00186 | 22.8285714286 | 0.0843193994786 |
| Methionine metabolism | C00114,C00170,C00315 | 3.2612244898 | 0.0853126353616 |
| Glycine, serine and threonine metabolism | C00258,C00213,C00597 | 2.97763975155 | 0.102615384655 |
| Gluconeogenesis | C00186,C00597,C00074 | 2.85357142857 | 0.11172856842 |
| Argininemia | C00062 | 11.4142857143 | 0.123703511329 |
| Hyperprolinemia type ii | C00077 | 7.60952380952 | 0.161348706546 |
| Argininosuccinic aciduria | C00062 | 7.60952380952 | 0.161348706546 |
| Biotin metabolism | C00047 | 7.60952380952 | 0.161348706546 |
| Biotinidase deficiency | C00047 | 7.60952380952 | 0.161348706546 |
| Glutamate metabolism | C00064,C00127 | 2.85357142857 | 0.181777473513 |
| Ammonia recycling | C00135,C00064 | 2.85357142857 | 0.181777473513 |
| Phenylacetate metabolism | C00064 | 5.70714285714 | 0.197333744168 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | C00214 | 5.70714285714 | 0.197333744168 |
| Glycerolipid metabolism | C00258,C00597 | 2.68571428571 | 0.19748681766 |
| Pyrimidine metabolism | C00214,C00475,C00064 | 2.07532467532 | 0.204347653454 |
| Glycolysis | C00074,C00597 | 2.4030075188 | 0.229267955908 |
| Histidine metabolism | C00135,C01152 | 2.07532467532 | 0.277264371331 |
| Prolidase deficiency(pd) | C00062,C00077 | 1.9850931677 | 0.293217438621 |
| Glycerol phosphate shuttle | C00016 | 3.2612244898 | 0.296061686834 |
| Arginine and proline metabolism | C00062,C00077 | 1.90238095238 | 0.309100943119 |
| Riboflavin metabolism | C00016 | 2.85357142857 | 0.32612310946 |
| Nucleotide sugars metabolism | C00052 | 2.85357142857 | 0.32612310946 |
| Pantothenate and coa biosynthesis | C00864 | 2.53650793651 | 0.354866673512 |
| Glutathione metabolism | C00127 | 2.53650793651 | 0.354866673512 |
| Betaine metabolism | C00114 | 2.53650793651 | 0.354866673512 |
| Lactose synthesis | C00052 | 2.28285714286 | 0.382351643634 |
| Beta-alanine metabolism | C00864 | 1.90238095238 | 0.43376932941 |
| Lysine degradation | C00047 | 1.90238095238 | 0.43376932941 |
| Glutaric aciduria type iii | C00047 | 1.75604395604 | 0.457807423915 |
| Sphingolipid metabolism | C00319 | 1.6306122449 | 0.480797921841 |
| Carnitine synthesis | C00047 | 1.42678571429 | 0.523821316553 |
| Pentose phosphate pathway | C00345 | 1.34285714286 | 0.543941542615 |
| Propanoate metabolism | C00183 | 1.34285714286 | 0.543941542615 |
| Phospholipid biosynthesis | C00114 | 1.26825396825 | 0.563189027333 |
| Purine metabolism | C00064,C00147 | 1.06179401993 | 0.576609879297 |
| Citric acid cycle | C00016 | 1.03766233766 | 0.632202153382 |
| Galactose metabolism | C00052 | 0.95119047619 | 0.662401597206 |
| Valine, leucine and isoleucine degradation | C00183 | 0.652244897959 | 0.788495211503 |
| Pathway | hits | oddsratio | pvalue |
| Prolidase deficiency(pd) | C00086,C00122,C00300,C00327 | 4.75595238095 | 0.0177222728599 |
| Arginine and proline metabolism | C00086,C00122,C00300,C00327 | 4.53977272727 | 0.0202424025148 |
| Transcription/translation | C00055,C00078,C00123,C00073 | 4.16145833333 | 0.0259030366808 |
| Ornithine transcarbamylase deficiency (otc deficiency) | C00295,C00327 | 9.9875 | 0.0295383180449 |
| Glycine n-methyltransferase deficiency | C00073 | inf | 0.0396634615384 |
| Glutaric aciduria type i | C00489 | inf | 0.0396634615384 |
| Gamma-glutamyltransferase deficiency | C00051 | inf | 0.0396634615384 |
| Methionine adenosyltransferase deficiency | C00073 | inf | 0.0396634615384 |
| Urea cycle | C00086,C00122,C00327 | 4.40625 | 0.044941564204 |
| Pyrimidine metabolism | C00055,C00295,C02642,C00299 | 3.12109375 | 0.0570075161487 |
| Hypermethioninemia | C00073 | 24.96875 | 0.0777080062794 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | C00300 | 24.96875 | 0.0777080062794 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | C00073 | 24.96875 | 0.0777080062794 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | C00300 | 24.96875 | 0.0777080062794 |
| Dihydropyrimidinase deficiency | C02642 | 24.96875 | 0.0777080062794 |
| Beta ureidopropionase deficiency | C02642 | 24.96875 | 0.0777080062794 |
| Ump synthase deiciency (orotic aciduria) | C00295 | 24.96875 | 0.0777080062794 |
| Aspartate metabolism | C00122,C00327 | 4.99375 | 0.0809198740366 |
| Oxidation of branched chain fatty acids | C03017,C00318 | 4.16145833333 | 0.105702096161 |
| Maple syrup urine disease | C00671 | 12.484375 | 0.114201574376 |
| Glutathione synthetase deficiency | C00051 | 12.484375 | 0.114201574376 |
| Cystathionine beta-synthase deficiency | C00073 | 12.484375 | 0.114201574376 |
| Mitochondrial electron transport chain | C00122,C00003 | 3.84134615385 | 0.118735663928 |
| Carnitine synthesis | C00318,C00003 | 3.32916666667 | 0.145813756735 |
| Thiamine metabolism | C00378 | 8.32291666667 | 0.149209176826 |
| Argininosuccinic aciduria | C00327 | 8.32291666667 | 0.149209176826 |
| Glutamate metabolism | C00003,C00051 | 3.12109375 | 0.15976035294 |
| Glycolysis | C00003,C00668 | 2.62828947368 | 0.202715562612 |
| Citrullinemia type i | C00327 | 4.99375 | 0.215012654944 |
| Citric acid cycle | C00122,C00003 | 2.37797619048 | 0.231914732567 |
| Pyruvaldehyde degradation | C00051 | 4.16145833333 | 0.245925044427 |
| Sulfate/sulfite metabolism | C00054 | 4.16145833333 | 0.245925044427 |
| Glycerol phosphate shuttle | C00003 | 3.56696428571 | 0.275584726828 |
| Malate-aspartate shuttle | C00003 | 3.56696428571 | 0.275584726828 |
| Gluconeogenesis | C00003,C00668 | 1.9975 | 0.290579614455 |
| Alpha linolenic acid and linoleic acid metabolism | C16300 | 3.12109375 | 0.304043898274 |
| Nucleotide sugars metabolism | C00668 | 3.12109375 | 0.304043898274 |
| Spermidine and spermine biosynthesis | C00073 | 3.12109375 | 0.304043898274 |
| Hartnup disorder | C00123 | 3.12109375 | 0.304043898274 |
| Pantothenate and coa biosynthesis | C01134 | 2.77430555556 | 0.331352520577 |
| Glutathione metabolism | C00051 | 2.77430555556 | 0.331352520577 |
| Betaine metabolism | C00073 | 2.77430555556 | 0.331352520577 |
| Ketone body metabolism | C00003 | 2.77430555556 | 0.331352520577 |
| Phosphatidylinositol phosphate metabolism | C00055 | 2.496875 | 0.357558419413 |
| Glucose-alanine cycle | C00003 | 2.26988636364 | 0.382707378084 |
| Nicotinate and nicotinamide metabolism | C00003 | 2.08072916667 | 0.406843227046 |
| Beta-alanine metabolism | C02642 | 2.08072916667 | 0.406843227046 |
| Phenylalanine and tyrosine metabolism | C00122 | 2.08072916667 | 0.406843227046 |
| 2-oxobutanoate degradation | C00003 | 2.08072916667 | 0.406843227046 |
| Valine, leucine and isoleucine degradation | C00671,C00123 | 1.46875 | 0.417816783993 |
| Beta oxidation of very long chain fatty acids | C00318 | 1.92067307692 | 0.430007929421 |
| Starch and sucrose metabolism | C00668 | 1.92067307692 | 0.430007929421 |
| Glutaric aciduria type iii | C00489 | 1.92067307692 | 0.430007929421 |
| Ethanol degradation | C00003 | 1.78348214286 | 0.452241662671 |
| Transfer of acetyl groups into mitochondria | C00003 | 1.66458333333 | 0.473582896593 |
| Pentose phosphate pathway | C00668 | 1.46875 | 0.513733651063 |
| Ammonia recycling | C00003 | 1.46875 | 0.513733651063 |
| Phospholipid biosynthesis | C00307 | 1.38715277778 | 0.532612226962 |
| Inositol metabolism | C00668 | 1.38715277778 | 0.532612226962 |
| Glycerolipid metabolism | C00003 | 1.38715277778 | 0.532612226962 |
| Inositol phosphate metabolism | C00668 | 1.31414473684 | 0.550736547187 |
| Hypoacetylaspartia | C00122 | 1.31414473684 | 0.550736547187 |
| Methionine metabolism | C00073 | 1.08559782609 | 0.616291687208 |
| Histidine metabolism | C00003 | 1.08559782609 | 0.616291687208 |
| Galactose metabolism | C00668 | 1.04036458333 | 0.631084180576 |
| Glycine, serine and threonine metabolism | C00300 | 0.99875 | 0.645289807227 |
| Tryptophan metabolism | C00078 | 0.756628787879 | 0.740480188154 |
| Tyrosine metabolism | C00122 | 0.674831081081 | 0.77777248418 |
| Purine metabolism | C00387 | 0.567471590909 | 0.830311469438 |
| Pathway | hits | oddsratio | pvalue |
| Hartnup disorder | C00123,C00062,C00407,C00183,C00047 | 33.2916666667 | 1.06406814557e-05 |
| Transcription/translation | C00148,C00123,C00073,C00062,C00407,C00047,C00183 | 8.87777777778 | 9.56450241684e-05 |
| Lysinuric protein intolerance | C00062,C00047 | inf | 0.00143824395053 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | C00214,C00526 | 17.7555555556 | 0.0132760599343 |
| Glycine n-methyltransferase deficiency | C00073 | inf | 0.0373493975903 |
| Glycerol kinase deficiency | C00116 | inf | 0.0373493975903 |
| Methionine adenosyltransferase deficiency | C00073 | inf | 0.0373493975903 |
| Prolidase deficiency(pd) | C00086,C00148,C00062 | 3.63181818182 | 0.0677036541369 |
| Hypermethioninemia | C00073 | 26.6333333333 | 0.0732605512301 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | C00073 | 26.6333333333 | 0.0732605512301 |
| Iminoglycinuria | C00148 | 26.6333333333 | 0.0732605512301 |
| Saccharopinuria/hyperlysinemia ii | C00047 | 26.6333333333 | 0.0732605512301 |
| Prolinemia type ii | C00148 | 26.6333333333 | 0.0732605512301 |
| Arginine and proline metabolism | C00086,C00148,C00062 | 3.47391304348 | 0.0743502173734 |
| Hyperprolinemia type i | C00148 | 13.3166666667 | 0.107790506653 |
| Argininemia | C00062 | 13.3166666667 | 0.107790506653 |
| Cystathionine beta-synthase deficiency | C00073 | 13.3166666667 | 0.107790506653 |
| Hyperprolinemia type ii | C00148 | 8.87777777778 | 0.140993981195 |
| Argininosuccinic aciduria | C00062 | 8.87777777778 | 0.140993981195 |
| Biotin metabolism | C00047 | 8.87777777778 | 0.140993981195 |
| Biotinidase deficiency | C00047 | 8.87777777778 | 0.140993981195 |
| Propanoate metabolism | C01013,C00183 | 3.32916666667 | 0.145336382981 |
| Valine, leucine and isoleucine degradation | C00123,C00407,C00183 | 2.42121212121 | 0.153668090433 |
| Urea cycle | C00086,C00062 | 2.95925925926 | 0.171722159419 |
| Citrullinemia type i | C00047 | 5.32666666667 | 0.203629297071 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | C02140 | 3.80476190476 | 0.261561278917 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | C02140 | 3.80476190476 | 0.261561278917 |
| Alpha linolenic acid and linoleic acid metabolism | C16300 | 3.32916666667 | 0.288878224446 |
| Spermidine and spermine biosynthesis | C00073 | 3.32916666667 | 0.288878224446 |
| Betaine metabolism | C00073 | 2.95925925926 | 0.315153284091 |
| Lysine degradation | C00047 | 2.21944444444 | 0.388128254965 |
| Pyrimidine metabolism | C00526,C00214 | 1.56666666667 | 0.388817354075 |
| Oxidation of branched chain fatty acids | C03017 | 2.04871794872 | 0.410628876668 |
| Beta oxidation of very long chain fatty acids | C01571 | 2.04871794872 | 0.410628876668 |
| Glutaric aciduria type iii | C00047 | 2.04871794872 | 0.410628876668 |
| Carnitine synthesis | C00047 | 1.66458333333 | 0.473144043947 |
| Glycerolipid metabolism | C00116 | 1.47962962963 | 0.510981998155 |
| Methionine metabolism | C00073 | 1.15797101449 | 0.593794240135 |
| Histidine metabolism | C01152 | 1.15797101449 | 0.593794240135 |
| Galactose metabolism | C00116 | 1.10972222222 | 0.608539414088 |
| Fatty acid biosynthesis | C01571 | 0.859139784946 | 0.697437595493 |
| Steroidogenesis | C02140 | 0.832291666667 | 0.708318610041 |
| Tryptophan metabolism | C01717 | 0.807070707071 | 0.718796157074 |
| Purine metabolism | C00294 | 0.605303030303 | 0.811424385373 |
| Bile acid biosynthesis | C17337 | 0.554861111111 | 0.836720300522 |
| Pathway | hits | oddsratio | pvalue |
| Alpha linolenic acid and linoleic acid metabolism | C06427,C03242,C01595,C06428 | 14.5272727273 | 0.000910089861541 |
| Phenylketonuria | C00166,C00079 | 12.1060606061 | 0.0259348978847 |
| 5-oxoprolinuria | C01879 | inf | 0.0533175355451 |
| Ornithine aminotransferase deficiency (oat deficiency) | C00077 | inf | 0.0533175355451 |
| Fatty acid biosynthesis | C00249,C06424,C06423,C02679 | 2.59415584416 | 0.0923543379257 |
| Tyrosinemia type 3 (tyro3) | C00079 | 18.1590909091 | 0.103732578031 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | C00079 | 18.1590909091 | 0.103732578031 |
| Dihydropyrimidinase deficiency | C02642 | 18.1590909091 | 0.103732578031 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | C00021 | 18.1590909091 | 0.103732578031 |
| Beta ureidopropionase deficiency | C02642 | 18.1590909091 | 0.103732578031 |
| Phenylalanine and tyrosine metabolism | C00166,C00079 | 3.30165289256 | 0.151291233984 |
| Maple syrup urine disease | C00671 | 9.07954545455 | 0.151406377072 |
| Glutathione synthetase deficiency | C01879 | 9.07954545455 | 0.151406377072 |
| Beta oxidation of very long chain fatty acids | C06423,C02679 | 3.02651515152 | 0.170381243524 |
| Hyperprolinemia type ii | C00077 | 6.05303030303 | 0.19649104417 |
| Obesity / metabolic syndrome | C00249 | 6.05303030303 | 0.19649104417 |
| Carnitine synthesis | C01181,C00021 | 2.42121212121 | 0.229340625529 |
| Homocysteine degradation | C00109 | 3.02651515152 | 0.317605169898 |
| Ornithine transcarbamylase deficiency (otc deficiency) | C00077 | 3.02651515152 | 0.317605169898 |
| Methionine metabolism | C00021,C00109 | 1.65082644628 | 0.367454343649 |
| Galactose metabolism | C00159,C00089 | 1.5790513834 | 0.386488920524 |
| Riboflavin metabolism | C00255 | 2.26988636364 | 0.387825620672 |
| Spermidine and spermine biosynthesis | C00077 | 2.26988636364 | 0.387825620672 |
| Glutathione metabolism | C01879 | 2.01767676768 | 0.420120869288 |
| Betaine metabolism | C00021 | 2.01767676768 | 0.420120869288 |
| Transcription/translation | C00078,C00079 | 1.39685314685 | 0.441823467991 |
| Beta-alanine metabolism | C02642 | 1.51325757576 | 0.506946411721 |
| 2-oxobutanoate degradation | C00109 | 1.51325757576 | 0.506946411721 |
| Starch and sucrose metabolism | C00089 | 1.39685314685 | 0.532836040042 |
| Ammonia recycling | C00785 | 1.06818181818 | 0.623252833475 |
| Fructose and mannose degradation | C00159 | 1.06818181818 | 0.623252833475 |
| Insulin signalling | C00249 | 1.00883838384 | 0.642920608989 |
| Glycerolipid metabolism | C00249 | 1.00883838384 | 0.642920608989 |
| Urea cycle | C00077 | 0.955741626794 | 0.66154004421 |
| Citric acid cycle | C00417 | 0.82541322314 | 0.711662942138 |
| Histidine metabolism | C00785 | 0.7895256917 | 0.726628533375 |
| Prolidase deficiency(pd) | C00077 | 0.756628787879 | 0.740801017244 |
| Fatty acid elongation in mitochondria | C00249 | 0.726363636364 | 0.754223289078 |
| Glycine, serine and threonine metabolism | C00109 | 0.726363636364 | 0.754223289078 |
| Arginine and proline metabolism | C00077 | 0.726363636364 | 0.754223289078 |
| Fatty acid metabolism | C00249 | 0.648538961039 | 0.790383077349 |
| Tryptophan metabolism | C00078 | 0.550275482094 | 0.839018406583 |
| Pyrimidine metabolism | C02642 | 0.518831168831 | 0.855088156008 |
| Valine, leucine and isoleucine degradation | C00671 | 0.518831168831 | 0.855088156008 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | nan | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | nan | 1.0 |
| Glycine n-methyltransferase deficiency | | nan | 1.0 |
| 3-methylglutaconic aciduria type i | | nan | 1.0 |
| Oxidation of branched chain fatty acids | | nan | 1.0 |
| Caffeine metabolism | | nan | 1.0 |
| Glycerol phosphate shuttle | | nan | 1.0 |
| Pentose phosphate pathway | | nan | 1.0 |
| Sphingolipid metabolism | | nan | 1.0 |
| Tyrosinemia type 3 (tyro3) | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | nan | 1.0 |
| Nucleotide sugars metabolism | | nan | 1.0 |
| Fructose and mannose degradation | | nan | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | nan | 1.0 |
| Ethylmalonic encephalopathy | | nan | 1.0 |
| Aspartylglucosaminuria | | nan | 1.0 |
| Vinblastine pathway | | nan | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | nan | 1.0 |
| Adefovir dipivoxil pathway | | nan | 1.0 |
| Aica-ribosiduria | | nan | 1.0 |
| Fatty acid elongation in mitochondria | | nan | 1.0 |
| Amino sugar metabolism | | nan | 1.0 |
| Escitalopram pathway | | nan | 1.0 |
| Ethanol degradation | | nan | 1.0 |
| Androgen and estrogen metabolism | | nan | 1.0 |
| Lactic acidemia | | nan | 1.0 |
| Lysinuric protein intolerance | | nan | 1.0 |
| Glutaric aciduria type i | | nan | 1.0 |
| Riboflavin metabolism | | nan | 1.0 |
| Non ketotic hyperglycinemia | | nan | 1.0 |
| Phosphatidylinositol phosphate metabolism | | nan | 1.0 |
| Propionic acidemia | | nan | 1.0 |
| Globoid cell leukodystrophy | | nan | 1.0 |
| Hyperprolinemia type ii | | nan | 1.0 |
| Glycolysis | | nan | 1.0 |
| Hypermethioninemia | | nan | 1.0 |
| Sialidosis | | nan | 1.0 |
| Glycine, serine and threonine metabolism | | nan | 1.0 |
| Ammonia recycling | | nan | 1.0 |
| Familial hypercholanemia (fhca) | | nan | 1.0 |
| Nicotine pathway | | nan | 1.0 |
| Thiamine metabolism | | nan | 1.0 |
| Cysteine metabolism | | nan | 1.0 |
| Urea cycle | | nan | 1.0 |
| Steroid biosynthesis | | nan | 1.0 |
| Purine nucleoside phosphorylase deficiency | | nan | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | nan | 1.0 |
| Ubiquinone biosynthesis | | nan | 1.0 |
| Catecholamine biosynthesis | | nan | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | nan | 1.0 |
| Prolidase deficiency(pd) | | nan | 1.0 |
| Acute intermittent porphyria | | nan | 1.0 |
| Methionine metabolism | | nan | 1.0 |
| Adenosine deaminase deficiency | | nan | 1.0 |
| Acenocoumarol pathway | | nan | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | nan | 1.0 |
| Phenylacetate metabolism | | nan | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | nan | 1.0 |
| Beta oxidation of very long chain fatty acids | | nan | 1.0 |
| Corticotropin activation of cortisol production | | nan | 1.0 |
| Citric acid cycle | | nan | 1.0 |
| Glutamate metabolism | | nan | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | nan | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | nan | 1.0 |
| Zellweger syndrome | | nan | 1.0 |
| Argininosuccinic aciduria | | nan | 1.0 |
| Glycerolipid metabolism | | nan | 1.0 |
| Maple syrup urine disease | | nan | 1.0 |
| Leukotriene c4 synthesis deficiency | | nan | 1.0 |
| One carbon pool by folate | | nan | 1.0 |
| Nebivolol pathway | | nan | 1.0 |
| Taurine and hypotaurine metabolism | | nan | 1.0 |
| Desmosterolosis | | nan | 1.0 |
| Tyrosinemia type i | | nan | 1.0 |
| 3-methylglutaconic aciduria type iv | | nan | 1.0 |
| Adenylosuccinate lyase deficiency | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | nan | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | nan | 1.0 |
| Folate and pterine biosynthesis | | nan | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | nan | 1.0 |
| Pantothenate and coa biosynthesis | | nan | 1.0 |
| Histidinemia | | nan | 1.0 |
| Congenital bile acid synthesis defect type ii | | nan | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | nan | 1.0 |
| Metachromatic leukodystrophy (mld) | | nan | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | nan | 1.0 |
| Glutathione metabolism | | nan | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | nan | 1.0 |
| Transfer of acetyl groups into mitochondria | | nan | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | nan | 1.0 |
| Hypoacetylaspartia | | nan | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | nan | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | nan | 1.0 |
| Molybdenium cofactor deficiency | | nan | 1.0 |
| Gliclazide pathway | | nan | 1.0 |
| Hyperprolinemia type i | | nan | 1.0 |
| 5-oxoprolinuria | | nan | 1.0 |
| Phenylketonuria | | nan | 1.0 |
| Tenofovir pathway | | nan | 1.0 |
| Tamoxifen pathway | | nan | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | nan | 1.0 |
| Glibenclamide pathway | | nan | 1.0 |
| Citalopram pathway | | nan | 1.0 |
| Congenital bile acid synthesis defect type iii | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | nan | 1.0 |
| 3-methylglutaconic aciduria type iii | | nan | 1.0 |
| Fluorouracil pathway | | nan | 1.0 |
| Betaine metabolism | | nan | 1.0 |
| Phenprocoumon pathway | | nan | 1.0 |
| Repaglinide pathway | | nan | 1.0 |
| Steroidogenesis | | nan | 1.0 |
| Sialuria or french type sialuria | | nan | 1.0 |
| Retinol metabolism | | nan | 1.0 |
| Sarcosinemia | | nan | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | nan | 1.0 |
| Lesch-nyhan syndrome (lns) | | nan | 1.0 |
| Galactose metabolism | | nan | 1.0 |
| Phospholipid biosynthesis | | nan | 1.0 |
| Histidine metabolism | | nan | 1.0 |
| Insulin signalling | | nan | 1.0 |
| Hawkinsinuria | | nan | 1.0 |
| Paclitaxel pathway | | nan | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | nan | 1.0 |
| Gout or kelley-seegmiller syndrome | | nan | 1.0 |
| Glycerol kinase deficiency | | nan | 1.0 |
| Argininemia | | nan | 1.0 |
| Spermidine and spermine biosynthesis | | nan | 1.0 |
| Biotinidase deficiency | | nan | 1.0 |
| Degradation of superoxides | | nan | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | nan | 1.0 |
| Primary hyperoxaluria type i | | nan | 1.0 |
| Citrullinemia type i | | nan | 1.0 |
| Selenoamino acid metabolism | | nan | 1.0 |
| Eplerenone pathway | | nan | 1.0 |
| Nicotinate and nicotinamide metabolism | | nan | 1.0 |
| Fatty acid metabolism | | nan | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | nan | 1.0 |
| Galactosemia | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | nan | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | nan | 1.0 |
| Glucose transporter defect (sglt2) | | nan | 1.0 |
| Pyruvaldehyde degradation | | nan | 1.0 |
| Dihydropyrimidinase deficiency | | nan | 1.0 |
| Canavan disease | | nan | 1.0 |
| Glutathione synthetase deficiency | | nan | 1.0 |
| Spironolactone pathway | | nan | 1.0 |
| Beta-alanine metabolism | | nan | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | nan | 1.0 |
| Lysine degradation | | nan | 1.0 |
| Vincristine pathway | | nan | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | nan | 1.0 |
| Tryptophan metabolism | | nan | 1.0 |
| Iminoglycinuria | | nan | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | nan | 1.0 |
| Warfarin pathway | | nan | 1.0 |
| Biotin metabolism | | nan | 1.0 |
| Ketone body metabolism | | nan | 1.0 |
| Leigh syndrome | | nan | 1.0 |
| Arachidonic acid metabolism | | nan | 1.0 |
| Isovaleric aciduria | | nan | 1.0 |
| Tyrosine metabolism | | nan | 1.0 |
| Inositol metabolism | | nan | 1.0 |
| Butyrate metabolism | | nan | 1.0 |
| Vitamin k metabolism | | nan | 1.0 |
| Vitamin a deficiency | | nan | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | nan | 1.0 |
| Alanine metabolism | | nan | 1.0 |
| Gamma-glutamyltransferase deficiency | | nan | 1.0 |
| Starch and sucrose metabolism | | nan | 1.0 |
| Fatty acid biosynthesis | | nan | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | nan | 1.0 |
| Methylmalonic aciduria | | nan | 1.0 |
| Arginine and proline metabolism | | nan | 1.0 |
| Fluoxetine pathway | | nan | 1.0 |
| Alkaptonuria | | nan | 1.0 |
| Gaba-transaminase deficiency | | nan | 1.0 |
| Cystathionine beta-synthase deficiency | | nan | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | nan | 1.0 |
| Dicumarol pathway | | nan | 1.0 |
| Lactose intolerance | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | nan | 1.0 |
| Bile acid biosynthesis | | nan | 1.0 |
| Malate-aspartate shuttle | | nan | 1.0 |
| Propanoate metabolism | | nan | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | nan | 1.0 |
| Phenylalanine and tyrosine metabolism | | nan | 1.0 |
| Beta ureidopropionase deficiency | | nan | 1.0 |
| Phytanic acid peroxisomal oxidation | | nan | 1.0 |
| Malonic aciduria | | nan | 1.0 |
| Vindesine pathway | | nan | 1.0 |
| Docetaxel pathway | | nan | 1.0 |
| Porphyria variegata (pv) | | nan | 1.0 |
| Glutaric aciduria type iii | | nan | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | nan | 1.0 |
| Prolinemia type ii | | nan | 1.0 |
| Carnitine synthesis | | nan | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | nan | 1.0 |
| Valine, leucine and isoleucine degradation | | nan | 1.0 |
| Child syndrome | | nan | 1.0 |
| Beta-ketothiolase deficiency | | nan | 1.0 |
| Purine metabolism | | nan | 1.0 |
| Vitamin b6 metabolism | | nan | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Obesity / metabolic syndrome | | nan | 1.0 |
| D-arginine and d-ornithine metabolism | | nan | 1.0 |
| Pyruvate carboxylase deficiency | | nan | 1.0 |
| Homocysteine degradation | | nan | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | nan | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | nan | 1.0 |
| Desipramine pathway | | nan | 1.0 |
| Pyruvate metabolism | | nan | 1.0 |
| Capecitabine pathway | | nan | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | nan | 1.0 |
| Aspartate metabolism | | nan | 1.0 |
| Salla disease/infantile sialic acid storage disease | | nan | 1.0 |
| Pyrimidine metabolism | | nan | 1.0 |
| Methionine adenosyltransferase deficiency | | nan | 1.0 |
| Gluconeogenesis | | nan | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | nan | 1.0 |
| Inositol phosphate metabolism | | nan | 1.0 |
| Gaucher disease | | nan | 1.0 |
| Nateglinide pathway | | nan | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | nan | 1.0 |
| Renal glucosuria | | nan | 1.0 |
| 2-oxobutanoate degradation | | nan | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | nan | 1.0 |
| Hereditary coproporphyria (hcp) | | nan | 1.0 |
| Glucose-alanine cycle | | nan | 1.0 |
| Hartnup disorder | | nan | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | nan | 1.0 |
| Vinorelbine pathway | | nan | 1.0 |
| Sulfate/sulfite metabolism | | nan | 1.0 |
| Mitochondrial electron transport chain | | nan | 1.0 |
| Lactose degradation | | nan | 1.0 |
| Transcription/translation | | nan | 1.0 |
| Refsum disease | | nan | 1.0 |
| Imipramine pathway | | nan | 1.0 |
| Vasopressin regulation of water homeostasis | | nan | 1.0 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | nan | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | nan | 1.0 |
| Glycine n-methyltransferase deficiency | | nan | 1.0 |
| 3-methylglutaconic aciduria type i | | nan | 1.0 |
| Oxidation of branched chain fatty acids | | nan | 1.0 |
| Caffeine metabolism | | nan | 1.0 |
| Glycerol phosphate shuttle | | nan | 1.0 |
| Pentose phosphate pathway | | nan | 1.0 |
| Sphingolipid metabolism | | nan | 1.0 |
| Tyrosinemia type 3 (tyro3) | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | nan | 1.0 |
| Nucleotide sugars metabolism | | nan | 1.0 |
| Fructose and mannose degradation | | nan | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | nan | 1.0 |
| Ethylmalonic encephalopathy | | nan | 1.0 |
| Aspartylglucosaminuria | | nan | 1.0 |
| Vinblastine pathway | | nan | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | nan | 1.0 |
| Adefovir dipivoxil pathway | | nan | 1.0 |
| Aica-ribosiduria | | nan | 1.0 |
| Fatty acid elongation in mitochondria | | nan | 1.0 |
| Amino sugar metabolism | | nan | 1.0 |
| Escitalopram pathway | | nan | 1.0 |
| Ethanol degradation | | nan | 1.0 |
| Androgen and estrogen metabolism | | nan | 1.0 |
| Lactic acidemia | | nan | 1.0 |
| Lysinuric protein intolerance | | nan | 1.0 |
| Glutaric aciduria type i | | nan | 1.0 |
| Riboflavin metabolism | | nan | 1.0 |
| Non ketotic hyperglycinemia | | nan | 1.0 |
| Phosphatidylinositol phosphate metabolism | | nan | 1.0 |
| Propionic acidemia | | nan | 1.0 |
| Globoid cell leukodystrophy | | nan | 1.0 |
| Hyperprolinemia type ii | | nan | 1.0 |
| Glycolysis | | nan | 1.0 |
| Hypermethioninemia | | nan | 1.0 |
| Sialidosis | | nan | 1.0 |
| Glycine, serine and threonine metabolism | | nan | 1.0 |
| Ammonia recycling | | nan | 1.0 |
| Familial hypercholanemia (fhca) | | nan | 1.0 |
| Nicotine pathway | | nan | 1.0 |
| Thiamine metabolism | | nan | 1.0 |
| Cysteine metabolism | | nan | 1.0 |
| Urea cycle | | nan | 1.0 |
| Steroid biosynthesis | | nan | 1.0 |
| Purine nucleoside phosphorylase deficiency | | nan | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | nan | 1.0 |
| Ubiquinone biosynthesis | | nan | 1.0 |
| Catecholamine biosynthesis | | nan | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | nan | 1.0 |
| Prolidase deficiency(pd) | | nan | 1.0 |
| Acute intermittent porphyria | | nan | 1.0 |
| Methionine metabolism | | nan | 1.0 |
| Adenosine deaminase deficiency | | nan | 1.0 |
| Acenocoumarol pathway | | nan | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | nan | 1.0 |
| Phenylacetate metabolism | | nan | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | nan | 1.0 |
| Beta oxidation of very long chain fatty acids | | nan | 1.0 |
| Corticotropin activation of cortisol production | | nan | 1.0 |
| Citric acid cycle | | nan | 1.0 |
| Glutamate metabolism | | nan | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | nan | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | nan | 1.0 |
| Zellweger syndrome | | nan | 1.0 |
| Argininosuccinic aciduria | | nan | 1.0 |
| Glycerolipid metabolism | | nan | 1.0 |
| Maple syrup urine disease | | nan | 1.0 |
| Leukotriene c4 synthesis deficiency | | nan | 1.0 |
| One carbon pool by folate | | nan | 1.0 |
| Nebivolol pathway | | nan | 1.0 |
| Taurine and hypotaurine metabolism | | nan | 1.0 |
| Desmosterolosis | | nan | 1.0 |
| Tyrosinemia type i | | nan | 1.0 |
| 3-methylglutaconic aciduria type iv | | nan | 1.0 |
| Adenylosuccinate lyase deficiency | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | nan | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | nan | 1.0 |
| Folate and pterine biosynthesis | | nan | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | nan | 1.0 |
| Pantothenate and coa biosynthesis | | nan | 1.0 |
| Histidinemia | | nan | 1.0 |
| Congenital bile acid synthesis defect type ii | | nan | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | nan | 1.0 |
| Metachromatic leukodystrophy (mld) | | nan | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | nan | 1.0 |
| Glutathione metabolism | | nan | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | nan | 1.0 |
| Transfer of acetyl groups into mitochondria | | nan | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | nan | 1.0 |
| Hypoacetylaspartia | | nan | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | nan | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | nan | 1.0 |
| Molybdenium cofactor deficiency | | nan | 1.0 |
| Gliclazide pathway | | nan | 1.0 |
| Hyperprolinemia type i | | nan | 1.0 |
| 5-oxoprolinuria | | nan | 1.0 |
| Phenylketonuria | | nan | 1.0 |
| Tenofovir pathway | | nan | 1.0 |
| Tamoxifen pathway | | nan | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | nan | 1.0 |
| Glibenclamide pathway | | nan | 1.0 |
| Citalopram pathway | | nan | 1.0 |
| Congenital bile acid synthesis defect type iii | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | nan | 1.0 |
| 3-methylglutaconic aciduria type iii | | nan | 1.0 |
| Fluorouracil pathway | | nan | 1.0 |
| Betaine metabolism | | nan | 1.0 |
| Phenprocoumon pathway | | nan | 1.0 |
| Repaglinide pathway | | nan | 1.0 |
| Steroidogenesis | | nan | 1.0 |
| Sialuria or french type sialuria | | nan | 1.0 |
| Retinol metabolism | | nan | 1.0 |
| Sarcosinemia | | nan | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | nan | 1.0 |
| Lesch-nyhan syndrome (lns) | | nan | 1.0 |
| Galactose metabolism | | nan | 1.0 |
| Phospholipid biosynthesis | | nan | 1.0 |
| Histidine metabolism | | nan | 1.0 |
| Insulin signalling | | nan | 1.0 |
| Hawkinsinuria | | nan | 1.0 |
| Paclitaxel pathway | | nan | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | nan | 1.0 |
| Gout or kelley-seegmiller syndrome | | nan | 1.0 |
| Glycerol kinase deficiency | | nan | 1.0 |
| Argininemia | | nan | 1.0 |
| Spermidine and spermine biosynthesis | | nan | 1.0 |
| Biotinidase deficiency | | nan | 1.0 |
| Degradation of superoxides | | nan | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | nan | 1.0 |
| Primary hyperoxaluria type i | | nan | 1.0 |
| Citrullinemia type i | | nan | 1.0 |
| Selenoamino acid metabolism | | nan | 1.0 |
| Eplerenone pathway | | nan | 1.0 |
| Nicotinate and nicotinamide metabolism | | nan | 1.0 |
| Fatty acid metabolism | | nan | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | nan | 1.0 |
| Galactosemia | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | nan | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | nan | 1.0 |
| Glucose transporter defect (sglt2) | | nan | 1.0 |
| Pyruvaldehyde degradation | | nan | 1.0 |
| Dihydropyrimidinase deficiency | | nan | 1.0 |
| Canavan disease | | nan | 1.0 |
| Glutathione synthetase deficiency | | nan | 1.0 |
| Spironolactone pathway | | nan | 1.0 |
| Beta-alanine metabolism | | nan | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | nan | 1.0 |
| Lysine degradation | | nan | 1.0 |
| Vincristine pathway | | nan | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | nan | 1.0 |
| Tryptophan metabolism | | nan | 1.0 |
| Iminoglycinuria | | nan | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | nan | 1.0 |
| Warfarin pathway | | nan | 1.0 |
| Biotin metabolism | | nan | 1.0 |
| Ketone body metabolism | | nan | 1.0 |
| Leigh syndrome | | nan | 1.0 |
| Arachidonic acid metabolism | | nan | 1.0 |
| Isovaleric aciduria | | nan | 1.0 |
| Tyrosine metabolism | | nan | 1.0 |
| Inositol metabolism | | nan | 1.0 |
| Butyrate metabolism | | nan | 1.0 |
| Vitamin k metabolism | | nan | 1.0 |
| Vitamin a deficiency | | nan | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | nan | 1.0 |
| Alanine metabolism | | nan | 1.0 |
| Gamma-glutamyltransferase deficiency | | nan | 1.0 |
| Starch and sucrose metabolism | | nan | 1.0 |
| Fatty acid biosynthesis | | nan | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | nan | 1.0 |
| Methylmalonic aciduria | | nan | 1.0 |
| Arginine and proline metabolism | | nan | 1.0 |
| Fluoxetine pathway | | nan | 1.0 |
| Alkaptonuria | | nan | 1.0 |
| Gaba-transaminase deficiency | | nan | 1.0 |
| Cystathionine beta-synthase deficiency | | nan | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | nan | 1.0 |
| Dicumarol pathway | | nan | 1.0 |
| Lactose intolerance | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | nan | 1.0 |
| Bile acid biosynthesis | | nan | 1.0 |
| Malate-aspartate shuttle | | nan | 1.0 |
| Propanoate metabolism | | nan | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | nan | 1.0 |
| Phenylalanine and tyrosine metabolism | | nan | 1.0 |
| Beta ureidopropionase deficiency | | nan | 1.0 |
| Phytanic acid peroxisomal oxidation | | nan | 1.0 |
| Malonic aciduria | | nan | 1.0 |
| Vindesine pathway | | nan | 1.0 |
| Docetaxel pathway | | nan | 1.0 |
| Porphyria variegata (pv) | | nan | 1.0 |
| Glutaric aciduria type iii | | nan | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | nan | 1.0 |
| Prolinemia type ii | | nan | 1.0 |
| Carnitine synthesis | | nan | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | nan | 1.0 |
| Valine, leucine and isoleucine degradation | | nan | 1.0 |
| Child syndrome | | nan | 1.0 |
| Beta-ketothiolase deficiency | | nan | 1.0 |
| Purine metabolism | | nan | 1.0 |
| Vitamin b6 metabolism | | nan | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Obesity / metabolic syndrome | | nan | 1.0 |
| D-arginine and d-ornithine metabolism | | nan | 1.0 |
| Pyruvate carboxylase deficiency | | nan | 1.0 |
| Homocysteine degradation | | nan | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | nan | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | nan | 1.0 |
| Desipramine pathway | | nan | 1.0 |
| Pyruvate metabolism | | nan | 1.0 |
| Capecitabine pathway | | nan | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | nan | 1.0 |
| Aspartate metabolism | | nan | 1.0 |
| Salla disease/infantile sialic acid storage disease | | nan | 1.0 |
| Pyrimidine metabolism | | nan | 1.0 |
| Methionine adenosyltransferase deficiency | | nan | 1.0 |
| Gluconeogenesis | | nan | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | nan | 1.0 |
| Inositol phosphate metabolism | | nan | 1.0 |
| Gaucher disease | | nan | 1.0 |
| Nateglinide pathway | | nan | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | nan | 1.0 |
| Renal glucosuria | | nan | 1.0 |
| 2-oxobutanoate degradation | | nan | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | nan | 1.0 |
| Hereditary coproporphyria (hcp) | | nan | 1.0 |
| Glucose-alanine cycle | | nan | 1.0 |
| Hartnup disorder | | nan | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | nan | 1.0 |
| Vinorelbine pathway | | nan | 1.0 |
| Sulfate/sulfite metabolism | | nan | 1.0 |
| Mitochondrial electron transport chain | | nan | 1.0 |
| Lactose degradation | | nan | 1.0 |
| Transcription/translation | | nan | 1.0 |
| Refsum disease | | nan | 1.0 |
| Imipramine pathway | | nan | 1.0 |
| Vasopressin regulation of water homeostasis | | nan | 1.0 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | nan | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | nan | 1.0 |
| Glycine n-methyltransferase deficiency | | nan | 1.0 |
| 3-methylglutaconic aciduria type i | | nan | 1.0 |
| Oxidation of branched chain fatty acids | | nan | 1.0 |
| Caffeine metabolism | | nan | 1.0 |
| Glycerol phosphate shuttle | | nan | 1.0 |
| Pentose phosphate pathway | | nan | 1.0 |
| Sphingolipid metabolism | | nan | 1.0 |
| Tyrosinemia type 3 (tyro3) | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | nan | 1.0 |
| Nucleotide sugars metabolism | | nan | 1.0 |
| Fructose and mannose degradation | | nan | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | nan | 1.0 |
| Ethylmalonic encephalopathy | | nan | 1.0 |
| Aspartylglucosaminuria | | nan | 1.0 |
| Vinblastine pathway | | nan | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | nan | 1.0 |
| Adefovir dipivoxil pathway | | nan | 1.0 |
| Aica-ribosiduria | | nan | 1.0 |
| Fatty acid elongation in mitochondria | | nan | 1.0 |
| Amino sugar metabolism | | nan | 1.0 |
| Escitalopram pathway | | nan | 1.0 |
| Ethanol degradation | | nan | 1.0 |
| Androgen and estrogen metabolism | | nan | 1.0 |
| Lactic acidemia | | nan | 1.0 |
| Lysinuric protein intolerance | | nan | 1.0 |
| Glutaric aciduria type i | | nan | 1.0 |
| Riboflavin metabolism | | nan | 1.0 |
| Non ketotic hyperglycinemia | | nan | 1.0 |
| Phosphatidylinositol phosphate metabolism | | nan | 1.0 |
| Propionic acidemia | | nan | 1.0 |
| Globoid cell leukodystrophy | | nan | 1.0 |
| Hyperprolinemia type ii | | nan | 1.0 |
| Glycolysis | | nan | 1.0 |
| Hypermethioninemia | | nan | 1.0 |
| Sialidosis | | nan | 1.0 |
| Glycine, serine and threonine metabolism | | nan | 1.0 |
| Ammonia recycling | | nan | 1.0 |
| Familial hypercholanemia (fhca) | | nan | 1.0 |
| Nicotine pathway | | nan | 1.0 |
| Thiamine metabolism | | nan | 1.0 |
| Cysteine metabolism | | nan | 1.0 |
| Urea cycle | | nan | 1.0 |
| Steroid biosynthesis | | nan | 1.0 |
| Purine nucleoside phosphorylase deficiency | | nan | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | nan | 1.0 |
| Ubiquinone biosynthesis | | nan | 1.0 |
| Catecholamine biosynthesis | | nan | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | nan | 1.0 |
| Prolidase deficiency(pd) | | nan | 1.0 |
| Acute intermittent porphyria | | nan | 1.0 |
| Methionine metabolism | | nan | 1.0 |
| Adenosine deaminase deficiency | | nan | 1.0 |
| Acenocoumarol pathway | | nan | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | nan | 1.0 |
| Phenylacetate metabolism | | nan | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | nan | 1.0 |
| Beta oxidation of very long chain fatty acids | | nan | 1.0 |
| Corticotropin activation of cortisol production | | nan | 1.0 |
| Citric acid cycle | | nan | 1.0 |
| Glutamate metabolism | | nan | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | nan | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | nan | 1.0 |
| Zellweger syndrome | | nan | 1.0 |
| Argininosuccinic aciduria | | nan | 1.0 |
| Glycerolipid metabolism | | nan | 1.0 |
| Maple syrup urine disease | | nan | 1.0 |
| Leukotriene c4 synthesis deficiency | | nan | 1.0 |
| One carbon pool by folate | | nan | 1.0 |
| Nebivolol pathway | | nan | 1.0 |
| Taurine and hypotaurine metabolism | | nan | 1.0 |
| Desmosterolosis | | nan | 1.0 |
| Tyrosinemia type i | | nan | 1.0 |
| 3-methylglutaconic aciduria type iv | | nan | 1.0 |
| Adenylosuccinate lyase deficiency | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | nan | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | nan | 1.0 |
| Folate and pterine biosynthesis | | nan | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | nan | 1.0 |
| Pantothenate and coa biosynthesis | | nan | 1.0 |
| Histidinemia | | nan | 1.0 |
| Congenital bile acid synthesis defect type ii | | nan | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | nan | 1.0 |
| Metachromatic leukodystrophy (mld) | | nan | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | nan | 1.0 |
| Glutathione metabolism | | nan | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | nan | 1.0 |
| Transfer of acetyl groups into mitochondria | | nan | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | nan | 1.0 |
| Hypoacetylaspartia | | nan | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | nan | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | nan | 1.0 |
| Molybdenium cofactor deficiency | | nan | 1.0 |
| Gliclazide pathway | | nan | 1.0 |
| Hyperprolinemia type i | | nan | 1.0 |
| 5-oxoprolinuria | | nan | 1.0 |
| Phenylketonuria | | nan | 1.0 |
| Tenofovir pathway | | nan | 1.0 |
| Tamoxifen pathway | | nan | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | nan | 1.0 |
| Glibenclamide pathway | | nan | 1.0 |
| Citalopram pathway | | nan | 1.0 |
| Congenital bile acid synthesis defect type iii | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | nan | 1.0 |
| 3-methylglutaconic aciduria type iii | | nan | 1.0 |
| Fluorouracil pathway | | nan | 1.0 |
| Betaine metabolism | | nan | 1.0 |
| Phenprocoumon pathway | | nan | 1.0 |
| Repaglinide pathway | | nan | 1.0 |
| Steroidogenesis | | nan | 1.0 |
| Sialuria or french type sialuria | | nan | 1.0 |
| Retinol metabolism | | nan | 1.0 |
| Sarcosinemia | | nan | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | nan | 1.0 |
| Lesch-nyhan syndrome (lns) | | nan | 1.0 |
| Galactose metabolism | | nan | 1.0 |
| Phospholipid biosynthesis | | nan | 1.0 |
| Histidine metabolism | | nan | 1.0 |
| Insulin signalling | | nan | 1.0 |
| Hawkinsinuria | | nan | 1.0 |
| Paclitaxel pathway | | nan | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | nan | 1.0 |
| Gout or kelley-seegmiller syndrome | | nan | 1.0 |
| Glycerol kinase deficiency | | nan | 1.0 |
| Argininemia | | nan | 1.0 |
| Spermidine and spermine biosynthesis | | nan | 1.0 |
| Biotinidase deficiency | | nan | 1.0 |
| Degradation of superoxides | | nan | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | nan | 1.0 |
| Primary hyperoxaluria type i | | nan | 1.0 |
| Citrullinemia type i | | nan | 1.0 |
| Selenoamino acid metabolism | | nan | 1.0 |
| Eplerenone pathway | | nan | 1.0 |
| Nicotinate and nicotinamide metabolism | | nan | 1.0 |
| Fatty acid metabolism | | nan | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | nan | 1.0 |
| Galactosemia | | nan | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | nan | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | nan | 1.0 |
| Glucose transporter defect (sglt2) | | nan | 1.0 |
| Pyruvaldehyde degradation | | nan | 1.0 |
| Dihydropyrimidinase deficiency | | nan | 1.0 |
| Canavan disease | | nan | 1.0 |
| Glutathione synthetase deficiency | | nan | 1.0 |
| Spironolactone pathway | | nan | 1.0 |
| Beta-alanine metabolism | | nan | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | nan | 1.0 |
| Lysine degradation | | nan | 1.0 |
| Vincristine pathway | | nan | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | nan | 1.0 |
| Tryptophan metabolism | | nan | 1.0 |
| Iminoglycinuria | | nan | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | nan | 1.0 |
| Warfarin pathway | | nan | 1.0 |
| Biotin metabolism | | nan | 1.0 |
| Ketone body metabolism | | nan | 1.0 |
| Leigh syndrome | | nan | 1.0 |
| Arachidonic acid metabolism | | nan | 1.0 |
| Isovaleric aciduria | | nan | 1.0 |
| Tyrosine metabolism | | nan | 1.0 |
| Inositol metabolism | | nan | 1.0 |
| Butyrate metabolism | | nan | 1.0 |
| Vitamin k metabolism | | nan | 1.0 |
| Vitamin a deficiency | | nan | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | nan | 1.0 |
| Alanine metabolism | | nan | 1.0 |
| Gamma-glutamyltransferase deficiency | | nan | 1.0 |
| Starch and sucrose metabolism | | nan | 1.0 |
| Fatty acid biosynthesis | | nan | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | nan | 1.0 |
| Methylmalonic aciduria | | nan | 1.0 |
| Arginine and proline metabolism | | nan | 1.0 |
| Fluoxetine pathway | | nan | 1.0 |
| Alkaptonuria | | nan | 1.0 |
| Gaba-transaminase deficiency | | nan | 1.0 |
| Cystathionine beta-synthase deficiency | | nan | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | nan | 1.0 |
| Dicumarol pathway | | nan | 1.0 |
| Lactose intolerance | | nan | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | nan | 1.0 |
| Bile acid biosynthesis | | nan | 1.0 |
| Malate-aspartate shuttle | | nan | 1.0 |
| Propanoate metabolism | | nan | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | nan | 1.0 |
| Phenylalanine and tyrosine metabolism | | nan | 1.0 |
| Beta ureidopropionase deficiency | | nan | 1.0 |
| Phytanic acid peroxisomal oxidation | | nan | 1.0 |
| Malonic aciduria | | nan | 1.0 |
| Vindesine pathway | | nan | 1.0 |
| Docetaxel pathway | | nan | 1.0 |
| Porphyria variegata (pv) | | nan | 1.0 |
| Glutaric aciduria type iii | | nan | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | nan | 1.0 |
| Prolinemia type ii | | nan | 1.0 |
| Carnitine synthesis | | nan | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | nan | 1.0 |
| Valine, leucine and isoleucine degradation | | nan | 1.0 |
| Child syndrome | | nan | 1.0 |
| Beta-ketothiolase deficiency | | nan | 1.0 |
| Purine metabolism | | nan | 1.0 |
| Vitamin b6 metabolism | | nan | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | nan | 1.0 |
| Obesity / metabolic syndrome | | nan | 1.0 |
| D-arginine and d-ornithine metabolism | | nan | 1.0 |
| Pyruvate carboxylase deficiency | | nan | 1.0 |
| Homocysteine degradation | | nan | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | nan | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | nan | 1.0 |
| Desipramine pathway | | nan | 1.0 |
| Pyruvate metabolism | | nan | 1.0 |
| Capecitabine pathway | | nan | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | nan | 1.0 |
| Aspartate metabolism | | nan | 1.0 |
| Salla disease/infantile sialic acid storage disease | | nan | 1.0 |
| Pyrimidine metabolism | | nan | 1.0 |
| Methionine adenosyltransferase deficiency | | nan | 1.0 |
| Gluconeogenesis | | nan | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | nan | 1.0 |
| Inositol phosphate metabolism | | nan | 1.0 |
| Gaucher disease | | nan | 1.0 |
| Nateglinide pathway | | nan | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | nan | 1.0 |
| Renal glucosuria | | nan | 1.0 |
| 2-oxobutanoate degradation | | nan | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | nan | 1.0 |
| Hereditary coproporphyria (hcp) | | nan | 1.0 |
| Glucose-alanine cycle | | nan | 1.0 |
| Hartnup disorder | | nan | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | nan | 1.0 |
| Vinorelbine pathway | | nan | 1.0 |
| Sulfate/sulfite metabolism | | nan | 1.0 |
| Mitochondrial electron transport chain | | nan | 1.0 |
| Lactose degradation | | nan | 1.0 |
| Transcription/translation | | nan | 1.0 |
| Refsum disease | | nan | 1.0 |
| Imipramine pathway | | nan | 1.0 |
| Vasopressin regulation of water homeostasis | | nan | 1.0 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | 0.0 | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | 0.0 | 1.0 |
| Glycine n-methyltransferase deficiency | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type i | | 0.0 | 1.0 |
| Oxidation of branched chain fatty acids | | 0.0 | 1.0 |
| Caffeine metabolism | | 0.0 | 1.0 |
| Glycerol phosphate shuttle | | 0.0 | 1.0 |
| Pentose phosphate pathway | | 0.0 | 1.0 |
| Sphingolipid metabolism | | 0.0 | 1.0 |
| Tyrosinemia type 3 (tyro3) | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | 0.0 | 1.0 |
| Nucleotide sugars metabolism | | 0.0 | 1.0 |
| Fructose and mannose degradation | | 0.0 | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | 0.0 | 1.0 |
| Ethylmalonic encephalopathy | | 0.0 | 1.0 |
| Aspartylglucosaminuria | | 0.0 | 1.0 |
| Vinblastine pathway | | 0.0 | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | 0.0 | 1.0 |
| Adefovir dipivoxil pathway | | 0.0 | 1.0 |
| Aica-ribosiduria | | 0.0 | 1.0 |
| Fatty acid elongation in mitochondria | | 0.0 | 1.0 |
| Amino sugar metabolism | | 0.0 | 1.0 |
| Escitalopram pathway | | 0.0 | 1.0 |
| Ethanol degradation | | 0.0 | 1.0 |
| Androgen and estrogen metabolism | | 0.0 | 1.0 |
| Lactic acidemia | | 0.0 | 1.0 |
| Lysinuric protein intolerance | | 0.0 | 1.0 |
| Glutaric aciduria type i | | 0.0 | 1.0 |
| Riboflavin metabolism | | 0.0 | 1.0 |
| Non ketotic hyperglycinemia | | 0.0 | 1.0 |
| Phosphatidylinositol phosphate metabolism | | 0.0 | 1.0 |
| Propionic acidemia | | 0.0 | 1.0 |
| Globoid cell leukodystrophy | | 0.0 | 1.0 |
| Hyperprolinemia type ii | | 0.0 | 1.0 |
| Glycolysis | | 0.0 | 1.0 |
| Hypermethioninemia | | 0.0 | 1.0 |
| Sialidosis | | 0.0 | 1.0 |
| Glycine, serine and threonine metabolism | | 0.0 | 1.0 |
| Ammonia recycling | | 0.0 | 1.0 |
| Familial hypercholanemia (fhca) | | 0.0 | 1.0 |
| Nicotine pathway | | 0.0 | 1.0 |
| Thiamine metabolism | | 0.0 | 1.0 |
| Cysteine metabolism | | 0.0 | 1.0 |
| Urea cycle | | 0.0 | 1.0 |
| Steroid biosynthesis | | 0.0 | 1.0 |
| Purine nucleoside phosphorylase deficiency | | 0.0 | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | 0.0 | 1.0 |
| Ubiquinone biosynthesis | | 0.0 | 1.0 |
| Catecholamine biosynthesis | | 0.0 | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | 0.0 | 1.0 |
| Prolidase deficiency(pd) | | 0.0 | 1.0 |
| Acute intermittent porphyria | | 0.0 | 1.0 |
| Methionine metabolism | | 0.0 | 1.0 |
| Adenosine deaminase deficiency | | 0.0 | 1.0 |
| Acenocoumarol pathway | | 0.0 | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | 0.0 | 1.0 |
| Phenylacetate metabolism | | 0.0 | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | 0.0 | 1.0 |
| Beta oxidation of very long chain fatty acids | | 0.0 | 1.0 |
| Corticotropin activation of cortisol production | | 0.0 | 1.0 |
| Citric acid cycle | | 0.0 | 1.0 |
| Glutamate metabolism | | 0.0 | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | 0.0 | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | 0.0 | 1.0 |
| Zellweger syndrome | | 0.0 | 1.0 |
| Argininosuccinic aciduria | | 0.0 | 1.0 |
| Glycerolipid metabolism | | 0.0 | 1.0 |
| Maple syrup urine disease | | 0.0 | 1.0 |
| Leukotriene c4 synthesis deficiency | | 0.0 | 1.0 |
| One carbon pool by folate | | 0.0 | 1.0 |
| Nebivolol pathway | | 0.0 | 1.0 |
| Taurine and hypotaurine metabolism | | 0.0 | 1.0 |
| Desmosterolosis | | 0.0 | 1.0 |
| Tyrosinemia type i | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iv | | 0.0 | 1.0 |
| Adenylosuccinate lyase deficiency | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | 0.0 | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | 0.0 | 1.0 |
| Folate and pterine biosynthesis | | 0.0 | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | 0.0 | 1.0 |
| Pantothenate and coa biosynthesis | | 0.0 | 1.0 |
| Histidinemia | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type ii | | 0.0 | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | 0.0 | 1.0 |
| Metachromatic leukodystrophy (mld) | | 0.0 | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | 0.0 | 1.0 |
| Glutathione metabolism | | 0.0 | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | 0.0 | 1.0 |
| Transfer of acetyl groups into mitochondria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | 0.0 | 1.0 |
| Hypoacetylaspartia | | 0.0 | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | 0.0 | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | 0.0 | 1.0 |
| Molybdenium cofactor deficiency | | 0.0 | 1.0 |
| Gliclazide pathway | | 0.0 | 1.0 |
| Hyperprolinemia type i | | 0.0 | 1.0 |
| 5-oxoprolinuria | | 0.0 | 1.0 |
| Phenylketonuria | | 0.0 | 1.0 |
| Tenofovir pathway | | 0.0 | 1.0 |
| Tamoxifen pathway | | 0.0 | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | 0.0 | 1.0 |
| Glibenclamide pathway | | 0.0 | 1.0 |
| Citalopram pathway | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type iii | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iii | | 0.0 | 1.0 |
| Fluorouracil pathway | | 0.0 | 1.0 |
| Betaine metabolism | | 0.0 | 1.0 |
| Phenprocoumon pathway | | 0.0 | 1.0 |
| Repaglinide pathway | | 0.0 | 1.0 |
| Steroidogenesis | | 0.0 | 1.0 |
| Sialuria or french type sialuria | | 0.0 | 1.0 |
| Retinol metabolism | | 0.0 | 1.0 |
| Sarcosinemia | | 0.0 | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | 0.0 | 1.0 |
| Lesch-nyhan syndrome (lns) | | 0.0 | 1.0 |
| Galactose metabolism | | 0.0 | 1.0 |
| Phospholipid biosynthesis | | 0.0 | 1.0 |
| Histidine metabolism | | 0.0 | 1.0 |
| Insulin signalling | | 0.0 | 1.0 |
| Hawkinsinuria | | 0.0 | 1.0 |
| Paclitaxel pathway | | 0.0 | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | 0.0 | 1.0 |
| Gout or kelley-seegmiller syndrome | | 0.0 | 1.0 |
| Glycerol kinase deficiency | | 0.0 | 1.0 |
| Argininemia | | 0.0 | 1.0 |
| Spermidine and spermine biosynthesis | | 0.0 | 1.0 |
| Biotinidase deficiency | | 0.0 | 1.0 |
| Degradation of superoxides | | 0.0 | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | 0.0 | 1.0 |
| Primary hyperoxaluria type i | | 0.0 | 1.0 |
| Citrullinemia type i | | 0.0 | 1.0 |
| Selenoamino acid metabolism | | 0.0 | 1.0 |
| Eplerenone pathway | | 0.0 | 1.0 |
| Nicotinate and nicotinamide metabolism | | 0.0 | 1.0 |
| Fatty acid metabolism | | 0.0 | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | 0.0 | 1.0 |
| Galactosemia | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | 0.0 | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | 0.0 | 1.0 |
| Glucose transporter defect (sglt2) | | 0.0 | 1.0 |
| Pyruvaldehyde degradation | | 0.0 | 1.0 |
| Dihydropyrimidinase deficiency | | 0.0 | 1.0 |
| Canavan disease | | 0.0 | 1.0 |
| Glutathione synthetase deficiency | | 0.0 | 1.0 |
| Spironolactone pathway | | 0.0 | 1.0 |
| Beta-alanine metabolism | | 0.0 | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | 0.0 | 1.0 |
| Lysine degradation | | 0.0 | 1.0 |
| Vincristine pathway | | 0.0 | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | 0.0 | 1.0 |
| Tryptophan metabolism | | 0.0 | 1.0 |
| Iminoglycinuria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | 0.0 | 1.0 |
| Warfarin pathway | | 0.0 | 1.0 |
| Biotin metabolism | | 0.0 | 1.0 |
| Ketone body metabolism | | 0.0 | 1.0 |
| Leigh syndrome | | 0.0 | 1.0 |
| Arachidonic acid metabolism | | 0.0 | 1.0 |
| Isovaleric aciduria | | 0.0 | 1.0 |
| Tyrosine metabolism | | 0.0 | 1.0 |
| Inositol metabolism | | 0.0 | 1.0 |
| Butyrate metabolism | | 0.0 | 1.0 |
| Vitamin k metabolism | | 0.0 | 1.0 |
| Vitamin a deficiency | | 0.0 | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | 0.0 | 1.0 |
| Alanine metabolism | | 0.0 | 1.0 |
| Gamma-glutamyltransferase deficiency | | 0.0 | 1.0 |
| Starch and sucrose metabolism | | 0.0 | 1.0 |
| Fatty acid biosynthesis | | 0.0 | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | 0.0 | 1.0 |
| Methylmalonic aciduria | | 0.0 | 1.0 |
| Arginine and proline metabolism | | 0.0 | 1.0 |
| Fluoxetine pathway | | 0.0 | 1.0 |
| Alkaptonuria | | 0.0 | 1.0 |
| Gaba-transaminase deficiency | | 0.0 | 1.0 |
| Cystathionine beta-synthase deficiency | | 0.0 | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | 0.0 | 1.0 |
| Dicumarol pathway | | 0.0 | 1.0 |
| Lactose intolerance | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | 0.0 | 1.0 |
| Bile acid biosynthesis | | 0.0 | 1.0 |
| Malate-aspartate shuttle | | 0.0 | 1.0 |
| Propanoate metabolism | | 0.0 | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | 0.0 | 1.0 |
| Phenylalanine and tyrosine metabolism | | 0.0 | 1.0 |
| Beta ureidopropionase deficiency | | 0.0 | 1.0 |
| Phytanic acid peroxisomal oxidation | | 0.0 | 1.0 |
| Malonic aciduria | | 0.0 | 1.0 |
| Vindesine pathway | | 0.0 | 1.0 |
| Docetaxel pathway | | 0.0 | 1.0 |
| Porphyria variegata (pv) | | 0.0 | 1.0 |
| Glutaric aciduria type iii | | 0.0 | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | 0.0 | 1.0 |
| Prolinemia type ii | | 0.0 | 1.0 |
| Carnitine synthesis | | 0.0 | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | 0.0 | 1.0 |
| Valine, leucine and isoleucine degradation | | 0.0 | 1.0 |
| Child syndrome | | 0.0 | 1.0 |
| Beta-ketothiolase deficiency | | 0.0 | 1.0 |
| Purine metabolism | | 0.0 | 1.0 |
| Vitamin b6 metabolism | | 0.0 | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Obesity / metabolic syndrome | | 0.0 | 1.0 |
| D-arginine and d-ornithine metabolism | | 0.0 | 1.0 |
| Pyruvate carboxylase deficiency | | 0.0 | 1.0 |
| Homocysteine degradation | | 0.0 | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | 0.0 | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | 0.0 | 1.0 |
| Desipramine pathway | | 0.0 | 1.0 |
| Pyruvate metabolism | | 0.0 | 1.0 |
| Capecitabine pathway | | 0.0 | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | 0.0 | 1.0 |
| Aspartate metabolism | | 0.0 | 1.0 |
| Salla disease/infantile sialic acid storage disease | | 0.0 | 1.0 |
| Pyrimidine metabolism | | 0.0 | 1.0 |
| Methionine adenosyltransferase deficiency | | 0.0 | 1.0 |
| Gluconeogenesis | | 0.0 | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | 0.0 | 1.0 |
| Inositol phosphate metabolism | | 0.0 | 1.0 |
| Gaucher disease | | 0.0 | 1.0 |
| Nateglinide pathway | | 0.0 | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | 0.0 | 1.0 |
| Renal glucosuria | | 0.0 | 1.0 |
| 2-oxobutanoate degradation | | 0.0 | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | 0.0 | 1.0 |
| Hereditary coproporphyria (hcp) | | 0.0 | 1.0 |
| Glucose-alanine cycle | | 0.0 | 1.0 |
| Hartnup disorder | | 0.0 | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | 0.0 | 1.0 |
| Vinorelbine pathway | | 0.0 | 1.0 |
| Sulfate/sulfite metabolism | | 0.0 | 1.0 |
| Mitochondrial electron transport chain | | 0.0 | 1.0 |
| Lactose degradation | | 0.0 | 1.0 |
| Transcription/translation | | 0.0 | 1.0 |
| Refsum disease | | 0.0 | 1.0 |
| Imipramine pathway | | 0.0 | 1.0 |
| Vasopressin regulation of water homeostasis | | 0.0 | 1.0 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | 0.0 | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | 0.0 | 1.0 |
| Glycine n-methyltransferase deficiency | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type i | | 0.0 | 1.0 |
| Oxidation of branched chain fatty acids | | 0.0 | 1.0 |
| Caffeine metabolism | | 0.0 | 1.0 |
| Glycerol phosphate shuttle | | 0.0 | 1.0 |
| Pentose phosphate pathway | | 0.0 | 1.0 |
| Sphingolipid metabolism | | 0.0 | 1.0 |
| Tyrosinemia type 3 (tyro3) | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | 0.0 | 1.0 |
| Nucleotide sugars metabolism | | 0.0 | 1.0 |
| Fructose and mannose degradation | | 0.0 | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | 0.0 | 1.0 |
| Ethylmalonic encephalopathy | | 0.0 | 1.0 |
| Aspartylglucosaminuria | | 0.0 | 1.0 |
| Vinblastine pathway | | 0.0 | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | 0.0 | 1.0 |
| Adefovir dipivoxil pathway | | 0.0 | 1.0 |
| Aica-ribosiduria | | 0.0 | 1.0 |
| Fatty acid elongation in mitochondria | | 0.0 | 1.0 |
| Amino sugar metabolism | | 0.0 | 1.0 |
| Escitalopram pathway | | 0.0 | 1.0 |
| Ethanol degradation | | 0.0 | 1.0 |
| Androgen and estrogen metabolism | | 0.0 | 1.0 |
| Lactic acidemia | | 0.0 | 1.0 |
| Lysinuric protein intolerance | | 0.0 | 1.0 |
| Glutaric aciduria type i | | 0.0 | 1.0 |
| Riboflavin metabolism | | 0.0 | 1.0 |
| Non ketotic hyperglycinemia | | 0.0 | 1.0 |
| Phosphatidylinositol phosphate metabolism | | 0.0 | 1.0 |
| Propionic acidemia | | 0.0 | 1.0 |
| Globoid cell leukodystrophy | | 0.0 | 1.0 |
| Hyperprolinemia type ii | | 0.0 | 1.0 |
| Glycolysis | | 0.0 | 1.0 |
| Hypermethioninemia | | 0.0 | 1.0 |
| Sialidosis | | 0.0 | 1.0 |
| Glycine, serine and threonine metabolism | | 0.0 | 1.0 |
| Ammonia recycling | | 0.0 | 1.0 |
| Familial hypercholanemia (fhca) | | 0.0 | 1.0 |
| Nicotine pathway | | 0.0 | 1.0 |
| Thiamine metabolism | | 0.0 | 1.0 |
| Cysteine metabolism | | 0.0 | 1.0 |
| Urea cycle | | 0.0 | 1.0 |
| Steroid biosynthesis | | 0.0 | 1.0 |
| Purine nucleoside phosphorylase deficiency | | 0.0 | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | 0.0 | 1.0 |
| Ubiquinone biosynthesis | | 0.0 | 1.0 |
| Catecholamine biosynthesis | | 0.0 | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | 0.0 | 1.0 |
| Prolidase deficiency(pd) | | 0.0 | 1.0 |
| Acute intermittent porphyria | | 0.0 | 1.0 |
| Methionine metabolism | | 0.0 | 1.0 |
| Adenosine deaminase deficiency | | 0.0 | 1.0 |
| Acenocoumarol pathway | | 0.0 | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | 0.0 | 1.0 |
| Phenylacetate metabolism | | 0.0 | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | 0.0 | 1.0 |
| Beta oxidation of very long chain fatty acids | | 0.0 | 1.0 |
| Corticotropin activation of cortisol production | | 0.0 | 1.0 |
| Citric acid cycle | | 0.0 | 1.0 |
| Glutamate metabolism | | 0.0 | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | 0.0 | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | 0.0 | 1.0 |
| Zellweger syndrome | | 0.0 | 1.0 |
| Argininosuccinic aciduria | | 0.0 | 1.0 |
| Glycerolipid metabolism | | 0.0 | 1.0 |
| Maple syrup urine disease | | 0.0 | 1.0 |
| Leukotriene c4 synthesis deficiency | | 0.0 | 1.0 |
| One carbon pool by folate | | 0.0 | 1.0 |
| Nebivolol pathway | | 0.0 | 1.0 |
| Taurine and hypotaurine metabolism | | 0.0 | 1.0 |
| Desmosterolosis | | 0.0 | 1.0 |
| Tyrosinemia type i | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iv | | 0.0 | 1.0 |
| Adenylosuccinate lyase deficiency | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | 0.0 | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | 0.0 | 1.0 |
| Folate and pterine biosynthesis | | 0.0 | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | 0.0 | 1.0 |
| Pantothenate and coa biosynthesis | | 0.0 | 1.0 |
| Histidinemia | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type ii | | 0.0 | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | 0.0 | 1.0 |
| Metachromatic leukodystrophy (mld) | | 0.0 | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | 0.0 | 1.0 |
| Glutathione metabolism | | 0.0 | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | 0.0 | 1.0 |
| Transfer of acetyl groups into mitochondria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | 0.0 | 1.0 |
| Hypoacetylaspartia | | 0.0 | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | 0.0 | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | 0.0 | 1.0 |
| Molybdenium cofactor deficiency | | 0.0 | 1.0 |
| Gliclazide pathway | | 0.0 | 1.0 |
| Hyperprolinemia type i | | 0.0 | 1.0 |
| 5-oxoprolinuria | | 0.0 | 1.0 |
| Phenylketonuria | | 0.0 | 1.0 |
| Tenofovir pathway | | 0.0 | 1.0 |
| Tamoxifen pathway | | 0.0 | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | 0.0 | 1.0 |
| Glibenclamide pathway | | 0.0 | 1.0 |
| Citalopram pathway | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type iii | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iii | | 0.0 | 1.0 |
| Fluorouracil pathway | | 0.0 | 1.0 |
| Betaine metabolism | | 0.0 | 1.0 |
| Phenprocoumon pathway | | 0.0 | 1.0 |
| Repaglinide pathway | | 0.0 | 1.0 |
| Steroidogenesis | | 0.0 | 1.0 |
| Sialuria or french type sialuria | | 0.0 | 1.0 |
| Retinol metabolism | | 0.0 | 1.0 |
| Sarcosinemia | | 0.0 | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | 0.0 | 1.0 |
| Lesch-nyhan syndrome (lns) | | 0.0 | 1.0 |
| Galactose metabolism | | 0.0 | 1.0 |
| Phospholipid biosynthesis | | 0.0 | 1.0 |
| Histidine metabolism | | 0.0 | 1.0 |
| Insulin signalling | | 0.0 | 1.0 |
| Hawkinsinuria | | 0.0 | 1.0 |
| Paclitaxel pathway | | 0.0 | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | 0.0 | 1.0 |
| Gout or kelley-seegmiller syndrome | | 0.0 | 1.0 |
| Glycerol kinase deficiency | | 0.0 | 1.0 |
| Argininemia | | 0.0 | 1.0 |
| Spermidine and spermine biosynthesis | | 0.0 | 1.0 |
| Biotinidase deficiency | | 0.0 | 1.0 |
| Degradation of superoxides | | 0.0 | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | 0.0 | 1.0 |
| Primary hyperoxaluria type i | | 0.0 | 1.0 |
| Citrullinemia type i | | 0.0 | 1.0 |
| Selenoamino acid metabolism | | 0.0 | 1.0 |
| Eplerenone pathway | | 0.0 | 1.0 |
| Nicotinate and nicotinamide metabolism | | 0.0 | 1.0 |
| Fatty acid metabolism | | 0.0 | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | 0.0 | 1.0 |
| Galactosemia | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | 0.0 | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | 0.0 | 1.0 |
| Glucose transporter defect (sglt2) | | 0.0 | 1.0 |
| Pyruvaldehyde degradation | | 0.0 | 1.0 |
| Dihydropyrimidinase deficiency | | 0.0 | 1.0 |
| Canavan disease | | 0.0 | 1.0 |
| Glutathione synthetase deficiency | | 0.0 | 1.0 |
| Spironolactone pathway | | 0.0 | 1.0 |
| Beta-alanine metabolism | | 0.0 | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | 0.0 | 1.0 |
| Lysine degradation | | 0.0 | 1.0 |
| Vincristine pathway | | 0.0 | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | 0.0 | 1.0 |
| Tryptophan metabolism | | 0.0 | 1.0 |
| Iminoglycinuria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | 0.0 | 1.0 |
| Warfarin pathway | | 0.0 | 1.0 |
| Biotin metabolism | | 0.0 | 1.0 |
| Ketone body metabolism | | 0.0 | 1.0 |
| Leigh syndrome | | 0.0 | 1.0 |
| Arachidonic acid metabolism | | 0.0 | 1.0 |
| Isovaleric aciduria | | 0.0 | 1.0 |
| Tyrosine metabolism | | 0.0 | 1.0 |
| Inositol metabolism | | 0.0 | 1.0 |
| Butyrate metabolism | | 0.0 | 1.0 |
| Vitamin k metabolism | | 0.0 | 1.0 |
| Vitamin a deficiency | | 0.0 | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | 0.0 | 1.0 |
| Alanine metabolism | | 0.0 | 1.0 |
| Gamma-glutamyltransferase deficiency | | 0.0 | 1.0 |
| Starch and sucrose metabolism | | 0.0 | 1.0 |
| Fatty acid biosynthesis | | 0.0 | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | 0.0 | 1.0 |
| Methylmalonic aciduria | | 0.0 | 1.0 |
| Arginine and proline metabolism | | 0.0 | 1.0 |
| Fluoxetine pathway | | 0.0 | 1.0 |
| Alkaptonuria | | 0.0 | 1.0 |
| Gaba-transaminase deficiency | | 0.0 | 1.0 |
| Cystathionine beta-synthase deficiency | | 0.0 | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | 0.0 | 1.0 |
| Dicumarol pathway | | 0.0 | 1.0 |
| Lactose intolerance | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | 0.0 | 1.0 |
| Bile acid biosynthesis | | 0.0 | 1.0 |
| Malate-aspartate shuttle | | 0.0 | 1.0 |
| Propanoate metabolism | | 0.0 | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | 0.0 | 1.0 |
| Phenylalanine and tyrosine metabolism | | 0.0 | 1.0 |
| Beta ureidopropionase deficiency | | 0.0 | 1.0 |
| Phytanic acid peroxisomal oxidation | | 0.0 | 1.0 |
| Malonic aciduria | | 0.0 | 1.0 |
| Vindesine pathway | | 0.0 | 1.0 |
| Docetaxel pathway | | 0.0 | 1.0 |
| Porphyria variegata (pv) | | 0.0 | 1.0 |
| Glutaric aciduria type iii | | 0.0 | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | 0.0 | 1.0 |
| Prolinemia type ii | | 0.0 | 1.0 |
| Carnitine synthesis | | 0.0 | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | 0.0 | 1.0 |
| Valine, leucine and isoleucine degradation | | 0.0 | 1.0 |
| Child syndrome | | 0.0 | 1.0 |
| Beta-ketothiolase deficiency | | 0.0 | 1.0 |
| Purine metabolism | | 0.0 | 1.0 |
| Vitamin b6 metabolism | | 0.0 | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Obesity / metabolic syndrome | | 0.0 | 1.0 |
| D-arginine and d-ornithine metabolism | | 0.0 | 1.0 |
| Pyruvate carboxylase deficiency | | 0.0 | 1.0 |
| Homocysteine degradation | | 0.0 | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | 0.0 | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | 0.0 | 1.0 |
| Desipramine pathway | | 0.0 | 1.0 |
| Pyruvate metabolism | | 0.0 | 1.0 |
| Capecitabine pathway | | 0.0 | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | 0.0 | 1.0 |
| Aspartate metabolism | | 0.0 | 1.0 |
| Salla disease/infantile sialic acid storage disease | | 0.0 | 1.0 |
| Pyrimidine metabolism | | 0.0 | 1.0 |
| Methionine adenosyltransferase deficiency | | 0.0 | 1.0 |
| Gluconeogenesis | | 0.0 | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | 0.0 | 1.0 |
| Inositol phosphate metabolism | | 0.0 | 1.0 |
| Gaucher disease | | 0.0 | 1.0 |
| Nateglinide pathway | | 0.0 | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | 0.0 | 1.0 |
| Renal glucosuria | | 0.0 | 1.0 |
| 2-oxobutanoate degradation | | 0.0 | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | 0.0 | 1.0 |
| Hereditary coproporphyria (hcp) | | 0.0 | 1.0 |
| Glucose-alanine cycle | | 0.0 | 1.0 |
| Hartnup disorder | | 0.0 | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | 0.0 | 1.0 |
| Vinorelbine pathway | | 0.0 | 1.0 |
| Sulfate/sulfite metabolism | | 0.0 | 1.0 |
| Mitochondrial electron transport chain | | 0.0 | 1.0 |
| Lactose degradation | | 0.0 | 1.0 |
| Transcription/translation | | 0.0 | 1.0 |
| Refsum disease | | 0.0 | 1.0 |
| Imipramine pathway | | 0.0 | 1.0 |
| Vasopressin regulation of water homeostasis | | 0.0 | 1.0 |
| Pathway | hits | oddsratio | pvalue |
| Lactose synthesis | | 0.0 | 1.0 |
| Intracellular signalling through pgd2 receptor and prostaglandin d2 | | 0.0 | 1.0 |
| Glycine n-methyltransferase deficiency | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type i | | 0.0 | 1.0 |
| Oxidation of branched chain fatty acids | | 0.0 | 1.0 |
| Caffeine metabolism | | 0.0 | 1.0 |
| Glycerol phosphate shuttle | | 0.0 | 1.0 |
| Pentose phosphate pathway | | 0.0 | 1.0 |
| Sphingolipid metabolism | | 0.0 | 1.0 |
| Tyrosinemia type 3 (tyro3) | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 6 and serotonin | | 0.0 | 1.0 |
| Nucleotide sugars metabolism | | 0.0 | 1.0 |
| Fructose and mannose degradation | | 0.0 | 1.0 |
| 3-hydroxy-3-methylglutaryl-coa lyase deficiency | | 0.0 | 1.0 |
| Ethylmalonic encephalopathy | | 0.0 | 1.0 |
| Aspartylglucosaminuria | | 0.0 | 1.0 |
| Vinblastine pathway | | 0.0 | 1.0 |
| Alpha linolenic acid and linoleic acid metabolism | | 0.0 | 1.0 |
| Adefovir dipivoxil pathway | | 0.0 | 1.0 |
| Aica-ribosiduria | | 0.0 | 1.0 |
| Fatty acid elongation in mitochondria | | 0.0 | 1.0 |
| Amino sugar metabolism | | 0.0 | 1.0 |
| Escitalopram pathway | | 0.0 | 1.0 |
| Ethanol degradation | | 0.0 | 1.0 |
| Androgen and estrogen metabolism | | 0.0 | 1.0 |
| Lactic acidemia | | 0.0 | 1.0 |
| Lysinuric protein intolerance | | 0.0 | 1.0 |
| Glutaric aciduria type i | | 0.0 | 1.0 |
| Riboflavin metabolism | | 0.0 | 1.0 |
| Non ketotic hyperglycinemia | | 0.0 | 1.0 |
| Phosphatidylinositol phosphate metabolism | | 0.0 | 1.0 |
| Propionic acidemia | | 0.0 | 1.0 |
| Globoid cell leukodystrophy | | 0.0 | 1.0 |
| Hyperprolinemia type ii | | 0.0 | 1.0 |
| Glycolysis | | 0.0 | 1.0 |
| Hypermethioninemia | | 0.0 | 1.0 |
| Sialidosis | | 0.0 | 1.0 |
| Glycine, serine and threonine metabolism | | 0.0 | 1.0 |
| Ammonia recycling | | 0.0 | 1.0 |
| Familial hypercholanemia (fhca) | | 0.0 | 1.0 |
| Nicotine pathway | | 0.0 | 1.0 |
| Thiamine metabolism | | 0.0 | 1.0 |
| Cysteine metabolism | | 0.0 | 1.0 |
| Urea cycle | | 0.0 | 1.0 |
| Steroid biosynthesis | | 0.0 | 1.0 |
| Purine nucleoside phosphorylase deficiency | | 0.0 | 1.0 |
| Pyruvate dehydrogenase complex deficiency | | 0.0 | 1.0 |
| Ubiquinone biosynthesis | | 0.0 | 1.0 |
| Catecholamine biosynthesis | | 0.0 | 1.0 |
| Arginine: glycine amidinotransferase deficiency (agat deficiency) | | 0.0 | 1.0 |
| Prolidase deficiency(pd) | | 0.0 | 1.0 |
| Acute intermittent porphyria | | 0.0 | 1.0 |
| Methionine metabolism | | 0.0 | 1.0 |
| Adenosine deaminase deficiency | | 0.0 | 1.0 |
| Acenocoumarol pathway | | 0.0 | 1.0 |
| Smith-lemli-opitz syndrome (slos) | | 0.0 | 1.0 |
| Phenylacetate metabolism | | 0.0 | 1.0 |
| Cerebrotendinous xanthomatosis (ctx) | | 0.0 | 1.0 |
| Beta oxidation of very long chain fatty acids | | 0.0 | 1.0 |
| Corticotropin activation of cortisol production | | 0.0 | 1.0 |
| Citric acid cycle | | 0.0 | 1.0 |
| Glutamate metabolism | | 0.0 | 1.0 |
| Intracellular signalling through fsh receptor and follicle stimulating hormone | | 0.0 | 1.0 |
| Short chain acyl coa dehydrogenase deficiency (scad deficiency) | | 0.0 | 1.0 |
| Zellweger syndrome | | 0.0 | 1.0 |
| Argininosuccinic aciduria | | 0.0 | 1.0 |
| Glycerolipid metabolism | | 0.0 | 1.0 |
| Maple syrup urine disease | | 0.0 | 1.0 |
| Leukotriene c4 synthesis deficiency | | 0.0 | 1.0 |
| One carbon pool by folate | | 0.0 | 1.0 |
| Nebivolol pathway | | 0.0 | 1.0 |
| Taurine and hypotaurine metabolism | | 0.0 | 1.0 |
| Desmosterolosis | | 0.0 | 1.0 |
| Tyrosinemia type i | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iv | | 0.0 | 1.0 |
| Adenylosuccinate lyase deficiency | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2b and adenosine | | 0.0 | 1.0 |
| Lysosomal acid lipase deficiency (wolman disease) | | 0.0 | 1.0 |
| Folate and pterine biosynthesis | | 0.0 | 1.0 |
| Tyrosinemia type 2 (or richner-hanhart syndrome) | | 0.0 | 1.0 |
| Pantothenate and coa biosynthesis | | 0.0 | 1.0 |
| Histidinemia | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type ii | | 0.0 | 1.0 |
| Methylenetetrahydrofolate reductase deficiency (mthfrd) | | 0.0 | 1.0 |
| Metachromatic leukodystrophy (mld) | | 0.0 | 1.0 |
| 3-methylcrotonyl coa carboxylase deficiency type i | | 0.0 | 1.0 |
| Glutathione metabolism | | 0.0 | 1.0 |
| Pyruvate decarboxylase e1 component deficiency (pdhe1 deficiency) | | 0.0 | 1.0 |
| Transfer of acetyl groups into mitochondria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 3 or congenital adrenal hyperplasia due to 21-hydroxylase deficiency | | 0.0 | 1.0 |
| Hypoacetylaspartia | | 0.0 | 1.0 |
| 4-hydroxybutyric aciduria/succinic semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Hyperinsulinism-hyperammonemia syndrome | | 0.0 | 1.0 |
| Intracellular signalling through histamine h2 receptor and histamine | | 0.0 | 1.0 |
| Molybdenium cofactor deficiency | | 0.0 | 1.0 |
| Gliclazide pathway | | 0.0 | 1.0 |
| Hyperprolinemia type i | | 0.0 | 1.0 |
| 5-oxoprolinuria | | 0.0 | 1.0 |
| Phenylketonuria | | 0.0 | 1.0 |
| Tenofovir pathway | | 0.0 | 1.0 |
| Tamoxifen pathway | | 0.0 | 1.0 |
| Guanidinoacetate methyltransferase deficiency (gamt deficiency) | | 0.0 | 1.0 |
| Glibenclamide pathway | | 0.0 | 1.0 |
| Citalopram pathway | | 0.0 | 1.0 |
| Congenital bile acid synthesis defect type iii | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 7 and serotonin | | 0.0 | 1.0 |
| 3-methylglutaconic aciduria type iii | | 0.0 | 1.0 |
| Fluorouracil pathway | | 0.0 | 1.0 |
| Betaine metabolism | | 0.0 | 1.0 |
| Phenprocoumon pathway | | 0.0 | 1.0 |
| Repaglinide pathway | | 0.0 | 1.0 |
| Steroidogenesis | | 0.0 | 1.0 |
| Sialuria or french type sialuria | | 0.0 | 1.0 |
| Retinol metabolism | | 0.0 | 1.0 |
| Sarcosinemia | | 0.0 | 1.0 |
| Congenital erythropoietic porphyria (cep) or gunther disease | | 0.0 | 1.0 |
| Lesch-nyhan syndrome (lns) | | 0.0 | 1.0 |
| Galactose metabolism | | 0.0 | 1.0 |
| Phospholipid biosynthesis | | 0.0 | 1.0 |
| Histidine metabolism | | 0.0 | 1.0 |
| Insulin signalling | | 0.0 | 1.0 |
| Hawkinsinuria | | 0.0 | 1.0 |
| Paclitaxel pathway | | 0.0 | 1.0 |
| 2-hydroxyglutric aciduria (d and l form) | | 0.0 | 1.0 |
| Gout or kelley-seegmiller syndrome | | 0.0 | 1.0 |
| Glycerol kinase deficiency | | 0.0 | 1.0 |
| Argininemia | | 0.0 | 1.0 |
| Spermidine and spermine biosynthesis | | 0.0 | 1.0 |
| Biotinidase deficiency | | 0.0 | 1.0 |
| Degradation of superoxides | | 0.0 | 1.0 |
| Intracellular signalling through prostacyclin receptor and prostacyclin | | 0.0 | 1.0 |
| Primary hyperoxaluria type i | | 0.0 | 1.0 |
| Citrullinemia type i | | 0.0 | 1.0 |
| Selenoamino acid metabolism | | 0.0 | 1.0 |
| Eplerenone pathway | | 0.0 | 1.0 |
| Nicotinate and nicotinamide metabolism | | 0.0 | 1.0 |
| Fatty acid metabolism | | 0.0 | 1.0 |
| Mngie (mitochondrial neurogastrointestinal encephalopathy) | | 0.0 | 1.0 |
| Galactosemia | | 0.0 | 1.0 |
| Excitatory neural signalling through 5-htr 4 and serotonin | | 0.0 | 1.0 |
| 2-methyl-3-hydroxybutryl coa dehydrogenase deficiency | | 0.0 | 1.0 |
| Glucose transporter defect (sglt2) | | 0.0 | 1.0 |
| Pyruvaldehyde degradation | | 0.0 | 1.0 |
| Dihydropyrimidinase deficiency | | 0.0 | 1.0 |
| Canavan disease | | 0.0 | 1.0 |
| Glutathione synthetase deficiency | | 0.0 | 1.0 |
| Spironolactone pathway | | 0.0 | 1.0 |
| Beta-alanine metabolism | | 0.0 | 1.0 |
| Dimethylglycine dehydrogenase deficiency | | 0.0 | 1.0 |
| Lysine degradation | | 0.0 | 1.0 |
| Vincristine pathway | | 0.0 | 1.0 |
| S-adenosylhomocysteine (sah) hydrolase deficiency | | 0.0 | 1.0 |
| Tryptophan metabolism | | 0.0 | 1.0 |
| Iminoglycinuria | | 0.0 | 1.0 |
| Adrenal hyperplasia type 5 or congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency | | 0.0 | 1.0 |
| Warfarin pathway | | 0.0 | 1.0 |
| Biotin metabolism | | 0.0 | 1.0 |
| Ketone body metabolism | | 0.0 | 1.0 |
| Leigh syndrome | | 0.0 | 1.0 |
| Arachidonic acid metabolism | | 0.0 | 1.0 |
| Isovaleric aciduria | | 0.0 | 1.0 |
| Tyrosine metabolism | | 0.0 | 1.0 |
| Inositol metabolism | | 0.0 | 1.0 |
| Butyrate metabolism | | 0.0 | 1.0 |
| Vitamin k metabolism | | 0.0 | 1.0 |
| Vitamin a deficiency | | 0.0 | 1.0 |
| Aromatic l-aminoacid decarboxylase deficiency | | 0.0 | 1.0 |
| Alanine metabolism | | 0.0 | 1.0 |
| Gamma-glutamyltransferase deficiency | | 0.0 | 1.0 |
| Starch and sucrose metabolism | | 0.0 | 1.0 |
| Fatty acid biosynthesis | | 0.0 | 1.0 |
| 17-beta hydroxysteroid dehydrogenase iii deficiency | | 0.0 | 1.0 |
| Methylmalonic aciduria | | 0.0 | 1.0 |
| Arginine and proline metabolism | | 0.0 | 1.0 |
| Fluoxetine pathway | | 0.0 | 1.0 |
| Alkaptonuria | | 0.0 | 1.0 |
| Gaba-transaminase deficiency | | 0.0 | 1.0 |
| Cystathionine beta-synthase deficiency | | 0.0 | 1.0 |
| Congenital lipoid adrenal hyperplasia (clah) or lipoid cah | | 0.0 | 1.0 |
| Dicumarol pathway | | 0.0 | 1.0 |
| Lactose intolerance | | 0.0 | 1.0 |
| Intracellular signalling through adenosine receptor a2a and adenosine | | 0.0 | 1.0 |
| Bile acid biosynthesis | | 0.0 | 1.0 |
| Malate-aspartate shuttle | | 0.0 | 1.0 |
| Propanoate metabolism | | 0.0 | 1.0 |
| Saccharopinuria/hyperlysinemia ii | | 0.0 | 1.0 |
| Phenylalanine and tyrosine metabolism | | 0.0 | 1.0 |
| Beta ureidopropionase deficiency | | 0.0 | 1.0 |
| Phytanic acid peroxisomal oxidation | | 0.0 | 1.0 |
| Malonic aciduria | | 0.0 | 1.0 |
| Vindesine pathway | | 0.0 | 1.0 |
| Docetaxel pathway | | 0.0 | 1.0 |
| Porphyria variegata (pv) | | 0.0 | 1.0 |
| Glutaric aciduria type iii | | 0.0 | 1.0 |
| Dihydropyrimidine dehydrogenase deficiency (dhpd) | | 0.0 | 1.0 |
| Prolinemia type ii | | 0.0 | 1.0 |
| Carnitine synthesis | | 0.0 | 1.0 |
| Glycogen storage disease type 1a (gsd1a) or von gierke ddisease | | 0.0 | 1.0 |
| Valine, leucine and isoleucine degradation | | 0.0 | 1.0 |
| Child syndrome | | 0.0 | 1.0 |
| Beta-ketothiolase deficiency | | 0.0 | 1.0 |
| Purine metabolism | | 0.0 | 1.0 |
| Vitamin b6 metabolism | | 0.0 | 1.0 |
| Methylmalonate semialdehyde dehydrogenase deficiency | | 0.0 | 1.0 |
| Obesity / metabolic syndrome | | 0.0 | 1.0 |
| D-arginine and d-ornithine metabolism | | 0.0 | 1.0 |
| Pyruvate carboxylase deficiency | | 0.0 | 1.0 |
| Homocysteine degradation | | 0.0 | 1.0 |
| Xanthine dehydrogenase deficiency (xanthinuria) | | 0.0 | 1.0 |
| Chondrodysplasia punctata ii, x linked dominant (cdpx2) | | 0.0 | 1.0 |
| Desipramine pathway | | 0.0 | 1.0 |
| Pyruvate metabolism | | 0.0 | 1.0 |
| Capecitabine pathway | | 0.0 | 1.0 |
| Intracellular signalling through lhcgr receptor and luteinizing hormone/choriogonadotropin | | 0.0 | 1.0 |
| Aspartate metabolism | | 0.0 | 1.0 |
| Salla disease/infantile sialic acid storage disease | | 0.0 | 1.0 |
| Pyrimidine metabolism | | 0.0 | 1.0 |
| Methionine adenosyltransferase deficiency | | 0.0 | 1.0 |
| Gluconeogenesis | | 0.0 | 1.0 |
| Ump synthase deiciency (orotic aciduria) | | 0.0 | 1.0 |
| Inositol phosphate metabolism | | 0.0 | 1.0 |
| Gaucher disease | | 0.0 | 1.0 |
| Nateglinide pathway | | 0.0 | 1.0 |
| Methylmalonic aciduria due to cobalamin-related disorders | | 0.0 | 1.0 |
| Renal glucosuria | | 0.0 | 1.0 |
| 2-oxobutanoate degradation | | 0.0 | 1.0 |
| Ornithine aminotransferase deficiency (oat deficiency) | | 0.0 | 1.0 |
| Hereditary coproporphyria (hcp) | | 0.0 | 1.0 |
| Glucose-alanine cycle | | 0.0 | 1.0 |
| Hartnup disorder | | 0.0 | 1.0 |
| Ornithine transcarbamylase deficiency (otc deficiency) | | 0.0 | 1.0 |
| Vinorelbine pathway | | 0.0 | 1.0 |
| Sulfate/sulfite metabolism | | 0.0 | 1.0 |
| Mitochondrial electron transport chain | | 0.0 | 1.0 |
| Lactose degradation | | 0.0 | 1.0 |
| Transcription/translation | | 0.0 | 1.0 |
| Refsum disease | | 0.0 | 1.0 |
| Imipramine pathway | | 0.0 | 1.0 |
| Vasopressin regulation of water homeostasis | | 0.0 | 1.0 |